| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 50, Issue 1, 107-142, March 1998
Departments of Pharmacology and Toxicology, Biochemistry, and Medicine, School of Medicine and Biomedical Sciences, State University of New York, Buffalo and V.A. Medical Center, New York
I. Introduction
A. History
B. Methodology
1. Clearance.
2. Sperber technique in chickens.
3. Isolated perfused kidney.
4. Tissue Preparations.
5. Molecular biology.
II. Renal Pathways for the Biotransformation of Drugs
A. Cytochrome P450 Dependent Mixed Function Oxidase System
1. Cytochrome P450 in the kidney.
2. Drugs that induce cytochrome P450 proteins.
3. Specific renal cytochrome P450 enzymes.
4. Nondrug factors that affect cytochrome P450 enzymes in the kidney that may modulate kidney drug metabolism.
B. N-Oxidation (Flavin-Containing Monooxygenases)
C. Alcohol Oxidation
D. Aldehyde Oxidation
E. Oxidative Deamination (Monoamine Oxidase)
F. Aldehyde and Ketone Reduction
1. Aldehyde reductase.
2. Ketone reductase.
3. Other.
G. Hydrolysis Mechanisms
1. Ester and amide hydrolysis/carboxylesterase and amidase.
2. Epoxide hydrolysis.
III. Phase II: Synthetic Conjugation Pathways
A. Glucuronidation
1. Isoforms.
2. Substrates and kinetics.
3. Induction of renal glucuronyl transferase.
4. Localization.
5. Relative contribution of renal glucuronidation.
B. Sulfation
C. Methylation
1. N-methylation.
2. O-methylation.
3. S-methylation.
D. Acetylation
E. Glutathione Conjugation
F. Mercapturic Acid Synthesis
G. Amino Acid Conjugation
1. Glycine conjugation.
2. Glutamine conjugation.
H. Cysteine Conjugate-Lyase
IV. Localization of Drug Metabolizing Enzymes in the Kidney
V. Effects of Renal Metabolism
Acknowledgments
References
 |
I. Introduction |
|---|
 Top NextReferences
|
|---|
A. History
The kidneys have important physiological functions including
maintenance of water and electrolyte balance, synthesis, metabolism and
secretion of hormones, and excretion of the waste products from
metabolism. In addition, the kidneys play a major role in the excretion
of drugs, hormones, and xenobiotics. Mechanisms involved in the
transport of drugs in the proximal tubule in the secretory direction
have been amply reviewed (Bessighir and Roch-Ramel, 1988
; Pritchard and
Miller, 1993). Reabsorptive transport for organic compounds,
particularly amino acids (Zelikovic and Chesney, 1989; Silbernagl,
1992) and choline (Acara and Rennick, 1973; Acara et al., 1979) also
have been studied. The concepts associated with pH dependence in the
nonionic passive back diffusion of drugs are well-described (Roch-Ramel
et al., 1992). However, the role of the kidney in the metabolism of
both endogenous and exogenous compounds has not received appropriate
attention.
Most of the current knowledge about drug metabolism is based on studies
in which the liver was the experimental organ. It is now clear that the
kidney actively metabolizes many drugs, hormones, and xenobiotics
(Anders, 1980; Bock et al., 1990). In some cases, certain
biotransformations occur at a faster rate in the kidney than in the
liver; e.g., glycination of benzoic acid (Poon and Pang, 1995). Bowsher
et al. (1983) found histamine N-methyltransferase activity to be higher
in concentration in rat renal tissue than in any other organ. Gamma
glutamyl transferase activity in mammalian tissues is at its highest in
the kidney (Goldbarg et al., 1960; see Section III.F.).
The heterogeneity of the kidney makes it important to define the
regional distribution of enzyme systems on a cellular and subcellular
level. The human kidney has two distinct regions: an outer cortical
region and the inner medullary region. The medulla is divided into
several pyramids, the base of which is at the corticomedullary junction
and the apex of which approaches the renal pelvis, forming a papilla.
This heterogeneity is caused by three successive excretory systems that
develop during embryonic development; and the latter two, the
mesonephros and metanephros, contribute to the formation of the kidney.
The ureteric bud, a specialized structure of the mesonephric duct,
gives rise to the collecting ducts, calyces, pelvis, and ureter. The
metanephros gives rise to the glomerulus, proximal, and distal tubules.
Whereas most studies have been performed either in whole kidney or in cortical tissue, biotransformations have also been identified in the
medullary region (Toback et al., 1977a; Lohr and Acara, 1990).
Information accumulated over the past 20 years demonstrates a large capacity for metabolism in the kidney, leading to activation or inactivation of numerous compounds and providing a major route for drug disposition. In addition, the metabolic products produced by the kidney may exert significant toxic effects. The pattern of blood flow through the kidney, the acidity of the urine, and the urinary concentrating mechanism provide an environment that facilitates the concentration of particular compounds in the medullary/papillary zone of the kidney, and sometimes even, their precipitation (e.g., uric acid) with resultant damage. Such reactions will be presented in a general way because the action of toxins on the kidney is beyond the scope of this review.
In this review, various methods will be described that have been used to study renal metabolism of drugs, xenobiotics, hormones, and endogenous compounds. The various types of metabolic reactions that occur in the kidney will be presented along with the compounds that occupy those particular routes. The contribution of the particular metabolic pathways to the direction of movement of metabolite, into blood or into urine, provides an interrelationship between transport and metabolism.
B. Methodology
Several different methods have been used to study the role of the kidney in the metabolism of drugs and xenobiotics. These vary from in vivo techniques, such as clearance and the Sperber chicken preparation, to in vitro studies of metabolism using organelles such as mitochondria and microsomes and molecular biology in which genes encoding specific enzymes of metabolism have been identified. Each technique has contributed different information regarding the way in which compounds are handled by the kidney.
1. Clearance.
Historically, the contribution of the kidney to
the elimination of a particular drug was measured as renal clearance
(Moller et al., 1928). The term "clearance" must be defined because
it is being used to describe an ever increasing number of functional equations. Renal clearance as described by Homer Smith (1956) is "the
volume of plasma required to supply the quantity X excreted in urine
each minute" or the volume of plasma completely cleared of that
substance in 1 minute time. However, these two definitions are not the
same because what is "cleared" may not necessarily appear in the
urine.
).
Clearance methods, developed to quantify renal function, were the first
methods used to study in vivo renal metabolism (Toretti and Weiner,
1976; Tucker, 1981). Metabolism may be detected during infusion of a
radiolabeled compound when the label in the urine is identified as
something other than the original compound (Quebbemann and Rennick,
1969; Acara and Rennick, 1972; Toback et al., 1977a,b).
Monitoring the fate of radiolabeled compounds after infusion into the
renal artery has provided some insight into the kidney's capacity to
metabolize. Diamond and Quebbemann (1981) demonstrated clearance of
radiolabeled metabolite during steady-state infusion of radiolabeled
metabolite (true clearance) and measurement of the clearance of
unlabeled metabolite during steady-state infusion of radiolabeled
metabolite and unlabeled precursor (apparent clearance). The difference
between the apparent clearance and true clearance is the renal
contribution to formation of urinary metabolite.
Tremaine, Diamond and Quebbemann (1984, 1985) developed another
radioisotope technique, termed the specific activity difference ratio
(SADRb) technique. This involves the infusion of
radiolabeled precursor as well as the infusion of unlabeled metabolites
if not present endogenously. The technique permits the quantification
of renal formation and excretion of several metabolites if they are
excreted in measurable amounts. Specific activity ratio technique is a standard isotope dilution method. This is performed by a constant infusion of radiolabeled metabolite along with a constant infusion of
unlabeled precursor. The specific radioactivities of metabolites in
plasma and urine are subsequently measured. The ratio of the specific
activity of metabolite in urine to that in plasma when subtracted from
one indicates the fraction of urinary metabolite formed in the kidney
and excreted; thus, determining the in vivo renal contribution to
formation of a compound.
2. Sperber technique in chickens.
Birds have a renal portal
circulation, accessible through a leg vein, which permits the
administration of substances to the ipsilateral kidney. Sperber (1946)
demonstrated that when substrates transported by organic excretory
transport carriers were infused into the leg vein, they were excreted
in excess in the urine from the ipsilateral kidney. Substances entering
the general circulation were excreted by both kidneys equally. Because
the chicken has no bladder, ureters from either side may be isolated
for urine collection (Campbell, 1960). Thus, when contralateral
excretion is subtracted from ipsilateral excretion and blood flow
through this system is considered, a value is obtained that describes the efficiency by which the compound is removed from the blood by the
kidney. In measuring the excretion of the metabolites of an infused
substance, those excreted in excess by the infused kidney represent the
results of intrarenal metabolism.
).
Whereas urinary metabolites clearly reflect active biochemical pathways
qualitatively, conversion rates are difficult to determine. The
technique does not account for the reabsorptive route of the metabolites but only for that route that ends with the appearance of
the metabolite in the urine.
3. Isolated perfused kidney.
The isolated perfused kidney
preparation permits the measurement of excretion, reabsorption, and
renal metabolism. (Nishiitsutsuji-Uwo, 1967; Bowman, 1978; Nizet,
1978). Because the kidney is removed from the animal, the influence of
other organs and tissues is not present. Renal clearance and urinary
clearance may be determined for a given compound. As previously
indicated, a large renal clearance associated with a low urinary
clearance suggests a metabolic component. Kidneys may be perfused for
up to 2 h and samples of perfusate and urine collected for
appropriate analyses.
). The conversion of enalapril, an inhibitor of angiotensin
converting enzyme, to its metabolite, enalaprilat, and the transport of
drug and metabolite across the basolateral and luminal membranes using
constant flow single pass and recirculating isolated perfused rat
kidney preparations provided an intrinsic clearance for renal drug
metabolism as well as identifying membrane transport steps (de Lannoy
et al., 1990).
Glutathione content of isolated perfused kidney is consistently lower
than that observed in vivo (Ross et al., 1980) and the maximum rates of
drug metabolism may not be observed. Functional shortcomings include
low glomerular filtration rate relative to perfusate flow and excessive
delivery of filtrate to the distal tubule with decreased concentrating
ability (Maack, 1980, 1986).
4. Tissue Preparations.
a. KIDNEY SLICES. Kidney slices have been used for the study of renal uptake and metabolism for decades (Forster, 1948).
Kidneys are removed quickly after onset of anesthesia and kept chilled
during slicing and until the start of incubation. Slices, thin enough
to permit oxygen to reach all of the tissue, may be incubated for up to 2 h. At the termination of the experiment, slices are blotted on
filter paper and weighed. Analyses of media and tissues for substrate
and metabolites can reveal accumulation of substrate against a
concentration gradient; as well as metabolic routes and intracellular
and extracellular amounts of substrate and metabolites. Phospholipid metabolism from (14C)-choline was
studied in mouse kidney slices during renal compensatory growth by
Toback et al. (1974). Inner cortical slices were found to have enhanced synthesis of choline containing lipids during kidney regeneration (Toback et al., 1977b). Relative specific activities of enzymes have
been studied in dissected cortex, outer medulla, and inner medulla.
Choline dehydrogenase activity was shown to increase in cortex and not
change in the inner medulla during hypernatremia (Grossman and Hebert,
1989). Addition of dimethylaminoethanol, an analogue of choline and an
inhibitor of choline oxidase, to isolated perfused kidneys as well as
dissected tissue regions decreased betaine production from
14C-choline (Lohr and Acara, 1990). Toback et al.
(1977b) studied the phosphorylation of choline into choline
phosphoglycerides in different kidney regions.However, information regarding the direction of movement, i.e.,
reabsorptive versus excretory, is not obtained using kidney slices.
Some controversy exists regarding whether or not tubules are collapsed.
Uniformity of slices is important because substrate and oxygen should
reach all cells. Sometimes the innermost cells of the slice are not
exposed to the same concentrations as the surface cells (Foulkes,
1996). The reproducibility and viability of tissue slices were greatly
improved by the more recent introduction of automated procedures to
produce "precision cut" kidney slices (Smith et al., 1985).
b. ISOLATED TUBULES.
Tubule segments may be obtained by
several methods. Microdissection of large numbers of tubule segments
may be performed after perfusion of the kidney with a collagenase
containing buffer and incubation with collagenase. The tubule segments
can then be used for metabolic studies in which the tubules are
typically incubated with a radiolabeled compound. After incubation, the
tubules can be separated from the medium either by centrifugation or
rapid filtration. Specific nephron segments can be obtained by this method but the tissue yield is low. Development of microassays has
permitted the study of enzyme activities in these segments (Endou,
1983a; Schlondorff, 1986). Relatively homogeneous proximal tubule suspensions can be obtained in
greater quantity by density gradient centrifugation, and, with
oxygenation, remain viable for approximately 2 h. Obtaining suspensions
of tubule segments other than proximal is more difficult because they
constitute lower percentages of the kidney mass.
c. CELL CULTURE.
Cultured cells have become a more
popular tool for metabolic studies. In addition to primary cultures,
there are now many continuous kidney cell lines (e.g., MDCK, LLC-PK1,
OK, A6, JTC-12, BSC1) available for study (Handler and Burg, 1992). The LLC-PK1, OK, and JTC-12 cell lines are of proximal tubular origin.
Of these the LLC-PK1 cells, derived from the Hampshire pig, have been
best characterized. They have characteristics such as Na-dependent
glucose uptake, Na-dependent phosphate uptake, and Na-dependent amino
acid uptake, and high activities of several brush border enzymes. The
MDCK cell line is most characteristic of distal tubule, and the A6 cell
line resembles the collecting duct.Primary cultures of proximal renal tubules may also be grown for use in
studies of renal drug metabolism. This may be accomplished with tubules
obtained by microdissection or by macro separation techniques using
rabbit, rat, dog or human kidney. Metabolic studies of cells in culture are generally performed on cells
which have reached confluence. The cells are rinsed with a buffer free
of the metabolic substrate to be studied and then incubated for an
appropriate time with substrate generally radiolabeled. The experiment
is ended by aspirating the medium, rinsing the cells, and disrupting
the cells with NaOH, scraping, or sonication. The cell fractions can
then be further analyzed. Fry and colleagues (1978) found that liver and kidney cells demonstrate
similar conjugated metabolite patterns. Jones et al. (1979) found that
the specific activities for formation of glucuronide and sulfate
derivatives in the kidney were approximately 5% of those for liver
cells, although formation of sulfhydryl derivatives was proportionately
higher in kidney cells with paracetamol as substrate.
d. SUBCELLULAR FRACTIONS.
Small (100 nm diameter)
closed vesicles which form when cells are disrupted by homogenization
and sediment at 100,000 × g are identified as
microsomes. They consist primarily of membranes of endoplasmic
reticulum and have proven to be a valuable tool in studying synthetic
and metabolic functions of the cell. Microsomes from kidney cortex have
been used to study drug metabolism. After homogenization and
centrifugation at low speed, the resulting supernatant is centrifuged
at high speed for 60 min. The microsomal fraction is the pellet that is
resuspended for use in drug metabolism studies. Substrates are added to
the microsomal incubation medium to study rates of conversion to
metabolites. Animals may be pretreated with various drugs and
xenobiotics, and the effects of these compounds on microsomal enzyme
activity determined in vitro. In addition to studying metabolism by use
of microsomes, the cytosolic fraction (i.e., the supernatant from the
microsomal fractionation) of cells can be isolated and used alone or in
conjunction with the microsomal fraction.
5. Molecular biology. The increased use of molecular biology techniques in the past 15 years has heavily impacted on how we classify and identify proteins. When available, IUBMB enzyme numbers are given for the enzymes discussed in this review. However, many enzyme activities have only been studied in membrane fractions or using nucleic acid probes, and IUBMB numbers are not available. A parallel system based on genetic information has arisen. The advances in molecular biology have allowed isolated proteins to be cloned and sequenced. In many cases, especially caused by the ease of analysis and amplification of small amounts of nucleic acid materials, it is easier to study the genetic material rather than the protein. Genes are isolated in different organs and species on the basis of homology to known genes whose enzymatic activities have been studied at the protein level. The transcriptional regulation of these genes can be studied and hypothetical protein sequences deduced. The explosion of molecular biology data has led to the same gene being isolated during studies of different phenotypes. To put some order into the system, there are organizations devoted to specific organisms: HUGO Gene Nomenclature Committee for human genes (accessed through http://gdb.org/gdb) and the Mouse Gene Nomenclature Committee for mouse genes (accessed through the Jackson Laboratory web site: http://www.informatics.jax.org). In addition, specific gene families have their own nomenclature organizations, such as the P450 Nomenclature Committee identified in the P450 section.
Molecular biology studies can never completely supersede the biochemical studies of isolated enzymes. The study of a gene isolated in the kidney as a homologue of a well-studied liver enzyme is extremely useful. However, it is not guaranteed that the enzyme encoded by that gene, even if it shows the same transcriptional regulation, has the same function in the kidney. The researcher is advised to check the gene banks for homologous genes, but to realize also that the strictly molecular biology studies do not indicate that the protein encoded by that gene has the implied function under physiological conditions in the organ of interest. With these caveats in mind, the authors of this review have attempted to use the most recent molecular biology designations of specific genes isolated in the kidney. Enzymatic activities of genes isolated in the kidney as homologues of liver genes are mentioned in the review, but they may be described more generally if their specific activity in the kidney has not been demonstrated.| |
II. Renal Pathways for the Biotransformation of Drugs |
|---|
|
TopPreviousNextReferences
|
|---|
The authors have organized the description of the specific pathways by first presenting an overview of the general reaction, then a discussion of the specific enzyme involved, and finally the role of this reaction in kidney drug metabolism.
A. Cytochrome P450 Dependent Mixed Function Oxidase System
The most well-studied drug metabolism reaction in the kidney (as well as in the liver) is the cytochrome P450 (CYP) mixed function oxidase (MFO) reaction, which catalyzes the hydroxylation of a diverse group of drugs as shown below:
|
(1) |
The localization of P450 MFO in the kidney has been known since the
early 1960s, and the early work in this area has been reviewed (Anders
et al., 1980i). Except for fatty acid hydroxylation (Oliw, 1994), which
is found to have greater activity in the kidney than in the liver, it
is clear that the renal metabolic contribution of the MFO system is
much less than that of the liver.
There are multiple components of the MFO, and different proteins are
described below. Cytochrome P450 is a heme containing enzyme that
serves as the terminal oxidase component of the electron transfer
system present in the endoplasmic reticulum. The usual second component
of the system is the flavoprotein nicotinamide adenine dinucleotide
phosphate (NADPH) dependent cytochrome P450 reductase that transfers
reducing equivalents from NADPH to cytochrome P450. In addition,
phospholipid is required for MFO activity. The lipid
phosphatidylcholine appears to be required for the coupling of the
cytochrome P450 to NADPH-dependent cytochrome P450 reductase. In
addition, cytochrome b5 and cytochrome
b5 reductase can also donate an electron
from nicotinamide adenine dinucleotide, reduced (NADH) to
cytochrome P450 (Guengerich, 1993).
In contrast to the wide range of cytochrome P450 proteins present in
the cell, there appears to be a limited number of NADPH cytochrome P450
reductases. This enzyme contains 1 mole of flavin adenine dinucleotide
(FAD) and 1 mole of flavin mononucleotide per mole of flavoprotein and
is found in close association with cytochrome P450 in the endoplasmic
reticulum. NADPH cytochrome P450 oxidoreductase
(NADPH:ferricytochromoxidoreductase, E.C. 1.6.2.4) has a Mr of 78.275 kDa and is found in close association with cytochrome P450 in the
endoplasmic reticulum (O'Leary et al., 1996).
The enzyme activity of NADPH-cytochrome c reductase has been determined
to be 34 and 77 nmol/mg protein/min in rabbit and mouse kidney,
respectively (Litterst et al., 1975). Human kidney was found to have
10.9 nmol reduced product/mg protein/min (Jakobsson et al., 1978).
These values range from 15 to 70% of that concentration found in the
liver of the respective species.
Microsomal NADPH cytochrome c reductase activity was found in
decreasing amounts from cortex to inner medulla (Zenser et al., 1978;
Endou, 1983a,b). When isolated tubules were examined, the activity was
greatest in the proximal tubule, although detectable in the glomerulus,
distal tubule, and collecting tubule (Endou, 1983a,b). Induction by
xylene and its isomers was observed in rat kidney by Toftgard and
Nilsen (1982).
1. Cytochrome P450 in the kidney.
The various cytochrome P450
proteins not only display different substrate activities, but they also
display different regional and stereo selectivities so that the fate of
a chemical in a tissue will be determined not only by the total
cytochrome P450 concentration but also by the form(s) present in that
tissue. There are a variety of oxidative reactions catalyzed by the
cytochrome P450 system. These include aliphatic hydroxylations,
aromatic oxidation, alkene epoxidation, nitrogen dealkylation,
oxidative deamination, oxygen dealkylation, nitrogen oxidation,
oxidative desulfurization, oxidative dehalogenation and oxidative
denitrification (Wislocki et al., 1980). Not all isoforms of cytochrome
P450 have been identified in the kidney.
, will be given
whenever possible. The reader is referred to this review for
information on enzyme functions and species location of the P450
families and subfamilies. The italicized root symbol (CYP for human)
will be followed by an Arabic number denoting the family, a letter
representing the subfamily, and an Arabic number representing the gene
within the subfamily. The gene products of the CYP genes, messenger
ribonucleic acid (mRNA), and proteins will be referred to using all
capital letters. Information from Nelson et al. (1993) was used to
provide the new name replacing the old common names for P450 enzymes.
However, much of the earlier work was done using enzyme assays or
immunological techniques. Because it is not possible to verify that the
P450 enzymes studied biochemically actually represent the enzymes
encoded by the isolated genes common names will appear in this review in addition to the current nomenclature of Nelson et al. (1996).
The following protein isoforms of the CYP genes have been found in the
kidney from studies of enzymes. CYP1A1 and CYP1A2 enzyme activities
were found (Ioannides and Parke, 1990). CYP4A1 (P450 LA
) was present in normal kidneys (Hardwick
et al, 1987.) Untreated kidney was shown to have low CYP1A enzyme
activity, which this was induced by polycyclic aromatic hydrocarbons,
-napthoflavone, and 2-acetylaminoflourine (Ioannides and Parke,
1990).
Molecular biology techniques have helped to find cytochrome P450 genes
in the kidney. Members of the CYP2 and
CYP4 gene families were among the earliest genes found
in the kidney (Gonzalez, 1989). CYP4A11 deoxyribonucleic
acid (DNA) was cloned from a human kidney complementary
deoxyribonucleic acid (cDNA) library independently by Palmer et al.
(1993) and Imaoka et al. (1993). Messenger ribonucleic acid (mRNA)
related to CYP4A11 was found in liver and kidney (with the highest abundance in the kidney) using Northern blot analysis and
ribonuclease protection assays (Palmer, 1993). The CYP4A5, A6, and A7 genes have been found in rabbit
kidney by Johnson et al. (1990), whereas the rat CYP4A2
was isolated by Kimura et al. (1989a,b). CYP4A3 is also
present in the kidney, and CYP3A4 is expressed in 80%
of human kidneys (Parkinson, 1996).
a. LOCALIZATION.
The localization of microsomal
cytochrome P450 in various regions of the kidney has been examined
(table 1). P450 is found in highest
concentration in the cortex, with smaller amounts in the outer medulla
and more in the inner medulla in rabbits (Zenser et al., 1978;
Armbrecht et al., 1979; Mohandas et al., 1981b). Using an isolated
tubule preparation, Endou (1983b) investigated the distribution of P450
in rat and rabbit kidney. P450 was found to be localized to the
proximal tubule, with the highest concentration in the S2 and S3
segments. At the same time using proximal and distal tubule suspensions
and spectrophotometric means cytochrome P450 was found to be present in
largest quantities in the proximal tubules (Cojocel et al., 1983).
Other investigators subsequently confirmed the localization of
cytochrome P450 to the proximal tubule (Foster et al., 1986).
Immunochemical analysis has shown that P450IIE1 is located primarily in
proximal tubules with some staining in distal tubules (Hu et al.,
1993).
|
).In rabbits, a five-fold increase in cortical renal cytochrome P450
content was seen after exposure to 3-MC, whereas the outer medullary
activity was only able to be identified after 3-MC treatment (Zenser et
al., 1978; Armbrecht et al., 1979). Likewise, 3-MC caused induction of
renal microsomal P450 in rats (Endou, 1983b; Funae et al., 1985; Wilson
et al., 1990). A 3-MC-inducible form of cytochrome P448 (CYP4A7), which
catalyzed the hydroxylation of BP, has been isolated from the cortex of
rabbit kidneys (Kusunose et al., 1989) and cytochrome P1450
(CYP1A1), but not Ps450, was induced by 3-MC (Tuteja et
al., 1985). In vivo hybridization of CYP4A8 to rat kidney sections
showed this DNA to be present in the outer stripe of the outer medulla
or proximal tubule (Stromstedt et al., 1990).
2. Drugs that induce cytochrome P450 proteins. The following sections describe systems in which P450 protein have been reported to be induced by various drugs. The researcher is directed to these references for more specific information.
a. ANALGESICS. Oxidation of acetaminophen by P450 in the kidney was reported by Mohandas et al. (1981a,b).
Immunohistochemical studies have been done that colocalized
acetaminophen and CYP2E1 protein in damaged kidney tissue after
administration of acetaminophen to mice (Hart et al., 1995).
Acetaminophen, a commonly used analgesic, induced nephrotoxicity in
males or females treated with testosterone, which corresponded with the
induction of renal CYP2E1 protein in mice as shown by Western blot
analysis and enzymatic activity (Hoivik et al., 1995). These results
are consistent with metabolism of acetaminophen by CYP2E1 protein
causing toxicity. Note that nephrotoxicity has also been hypothesized
to be related to prostaglandin synthesis activity in the kidney (cf
section in lipid metabolism).
b. ANESTHETICS.
In rats, ether anesthesia caused
lowering of total CYP protein, CYP1A, and CYP2B activities, whereas
increases in CYP2E1 activity were found. These changes were more
pronounced in fasted rats (Liu et al., 1993).
c. BARBITURATES.
Isozymes of renal P450 have been found
to be inducible by polycyclic aromatic compounds and barbiturates.
Phenobarbital (PB) induced CYP enzymes in cortical microsomes from
rabbit but not from rat (Kuo et al., 1982). Specifically CYP1A1 and A2
enzymes were induced by PB (Ioannides and Parke, 1990). Multiple forms of CYP2B and CYP4B1 were shown to be induced in the kidney by PB using
molecular biology studies (Ryan et al., 1993).
d. CHEMOTHERAPEUTIC AGENTS.
It has been known for a
while that cis-diaminedichloroplatinum caused an increase in CYP enzyme
activity as measured by spectral methods (Jollie and Maines, 1985).
Cis-platinum was found to specifically induce renal CYP2C23 (Ohishi et
al., 1994), and this immunological result was not correlated with any
increase in lauric acid 
-hydroxylation activity.
e. ALCOHOL.
The CYP2E1 gene is an ethanol inducible
form of P450 that metabolizes substrates such as ethanol, acetone,
diethyl ether, p-nitrophenol, halothane, benzene, and
N-nitrosodimethylamine, and is expressed in rabbit kidney (Khani et
al., 1988). The protein encoded by CYP2E1 is sometimes referred to a
P450 3a, P4502E1, or P450alc.Alcohol was shown to induce P450 isozyme 3a (CYP2E1) in the kidney
using antibodies to the liver protein. This increased expression accompanied a seven-fold increase in the isozyme 3a dependent rate of
aniline and butanol metabolism in kidney microsomes (Ding et al.,
1986). Ethanol has been found to induce specifically isozyme CYP2E1 in
the kidney by 50 to 80% (Ueng et al., 1987) and 500% (Ding et al.,
1986). Cyp2e-1 (the mouse ortholog of CYP2E1) is present in kidney and
induced by alcohol (Thomas et al., 1987). In addition to alcohol CYP2E1
protein was induced by bacterial lipopolysaccharide (LPS) irritants.
Bacterial LPS also induced CYP4A2 and 4A3 along with CYP2E1 (Sewer et
al., 1997). Inhalation of alcohol vapor was found to be the best way to induce the
protein encoded by CYP2E1, as detected by immunoblotting, in the
proximal convoluted tubule of the rat kidney. This result correlated
with induction of chlorzoxazone hydroxylation in rat kidney microsomes
(Zerilli et al., 1995). The half-life of immunoreactive CYP2E1 protein
in kidney was found to be approximately 6 h (Roberts et al.,
1994). The CYP2E1 protein and gene can also be induced by pyridine (Kim
et al., 1992).
f. IMMUNOSUPPRESSIVE AGENTS.
Total kidney cytochrome
P450 levels were increased after exposure to cyclosporin, whereas
hepatic P450 decreased (Mayer et al., 1989). Using Western blot
analysis, Yoshimura et al. (1989) showed that cyclosporin A induced a
protein in rat kidney that cross reacted to rabbit CYP2B protein. In
rat renal microsomes obtained after treatment of the animal with
cyclosporin A, immunoblotting with antibody to rabbit CYP2B4 protein
did not show any increase of this protein. In addition, levels of cross
reacting material to CYP4A5 (P450 kd) was also found after treatment
(Yoshimura et al., 1993b). Western blots of the membrane protein from
rat kidney obtained using antibodies to enzyme P450LM2, (CYP2B4) showed no induction of this protein by rapamycin. However, there was an
increase in aminopyrine N-demethylase activity after rapamycin treatment (Yoshimura et al., 1993a). Cyclosporin A has been shown to
induce CYP4A2 in rat kidney (Nakamura et al., 1994).
3. Specific renal cytochrome P450 enzymes. The following sections discuss representative types of reactions attributed to kidney P450 enzymes (CYP) by purification and enzyme assay. These studies have found differences in activities in P450 enzymes isolated from kidneys of different species. If a specific P450 protein designation has been reported in the cited article the correct CYP nomenclature is given.
a. AROMATIC OXIDATION. This common reaction for drugs and xenobiotics that contain a benzene ring has been shown to occur in kidney microsomes. The hydroxylation of BP has been examined in rat (Mayer et al., 1989), rabbit (Zenser et al., 1978) hamster, and guinea
pig renal microsomes (Smith et al., 1986). Likewise, the hydroxylation
of aniline and biphenyl in various species was found to occur at low
levels of activity (Litterst et al., 1975).
b. N-DEALKYLATION.
N-dealkylation occurs in the
metabolism of drugs containing an alkyl group attached to an amine. In
all instances, its activity in the kidney is found to be equal to or
less than that of the liver (Orrhenius et al., 1973; Litterst et al.,
1975). The most commonly used substrate, aminopyrine (AP), undergoes
N-dealkylation in mouse, rat, rabbit, hamster, guinea pig, and human
kidney. Using AP as substrate, catalytic activity of human renal
cytochrome P450 was demonstrated in a reconstituted system using rat
NADPH-cytochrome P450 reductase and rat cytochrome b5
(Imaoka et al., 1990a). Zenser et al. (1978) examined the demethylation of AP in microsomes
from cortex, outer medulla, and inner medulla of rabbit kidney and
found activity only in the cortex, which was approximately one-third
that of liver. Pretreatment with 3-MC induced cortical activity and
caused appearance of activity in the outer medulla (Zenser et al.,
1978).N-demethylation of benzphetamine was demonstrated in rabbit renal
microsomes, but not in rat. The activity was induced three-fold by PB
treatment (Kuo et al., 1982). Likewise, benzphetamine demethylation was
induced by PB in renal microsomes from hamsters. Activity was 5 to 10%
that seen in liver (Smith et al., 1986).
O-DEALKYLATION.
Oxygen dealkylation occurs in the
metabolism of drugs containing an ether group. Renal cytochrome P450
2C23 (k2), A8(k-4), and 4A2(k-5) have been shown to catalyze the
O-deethylation of 7 ethoxycoumarin in a reconstituted system (Imaoka et
al., 1990a). Enzyme activity was demonstrated in microsomes from rat
and rabbit kidney. PB induced activity only in rabbits (Kuo et al.,
1982) and a two-fold induction was seen with ethanol (Ueng et al.,
1987). O-deethylation of 7-ethoxycoumarin and exthoxyresorufin in renal microsomes was approximately 15% that of liver in hamster, but much
less in guinea pig (Smith et al., 1986). No induction of ethoxycoumarin
deethylase by PB, polybrominated byphenyl or -napthoflavone (-NF)
occurred. Ethoxyresorufin deethylase activity in renal microsomes was
less than 10% that of liver in both hamster and guinea pig and
activity was induced by -NF (Smith et al., 1986). Rat kidney
activity was induced by xylene (Toftgard and Nilsen, 1982). Cytochrome
b5 independent O-dealkylation using 7-ethoxycoumarin was
found in rat and human kidney (Imaoka et al., 1990a). Cojocel et al.
(1983) reported O-deethylation of 7-ethoxycoumarin to be highest in the
proximal tubule fraction of the kidney. O-dealkylation of
ethoxyresorufin was shown in rat kidney microsomes exposed to the
polychlorinated biphenyl (PCB), Aroclor, by Beebe et al. (1995) and by
exposure to the pesticide Fenarimol (Paolini et al., 1996).
c. OXIDATIVE DEHALOGENATION.
Halogenated organic
compounds, such as general anesthetics, undergo oxidative
dehalogenation to the corresponding alcohol or acid. Renal microsomes
metabolize dichloromethane at a rate 5% that of liver microsomes
(Kubic and Anders, 1975).
4. Nondrug factors that affect cytochrome P450 enzymes in the kidney that may modulate kidney drug metabolism. In addition to being induced by drugs, various cytochrome P450s are induced by endogenous substrates, hormones, toxins, and various metabolic states. The presence of these additional effectors of P450 metabolism could affect the metabolism of drugs in the kidney. Below are representatives of these nondrug modulators on P450 function and expression in the rabbit kidney.
a. ENDOGENOUS LIPID METABOLISM. MFO and therefore P450 enzymes have been well-documented as playing a role in fatty acid and steroid metabolism in the liver. The kidney has been recently shown to be a site of these metabolic reactions. Expression of CYP3A, which catalyzes the 6-hydroxylation of endogenous steroids, has been found in amphibian (A6) renal cells and rat kidney and human kidney microsomes (Schuetz et al., 1992). In immunochemistry, studies using antibodies
raised to an adrenal cortex enzyme (steroid 21-hydroxylase),
immunoreactive protein was localized in the distal, cortical, and
medullary collecting tubules of the kidney. CYP21A1
(P450C21) enzymatic activity had previously been reported
in the bovine kidney (Sasano et al., 1988).The kidney has many P450s that are involved in fatty acid metabolism.
The general role of cytochrome P450 in the arachidonate cascade has
been reviewed by Capdevila and colleagues (1992). Zenser recognized in
1979 that there were at least two separate pathways for arachidonic
acid metabolism in the kidney. One pathway was the prostaglandin
cyclooxygenase pathway, whereas a second pathway involved the
NADPH-dependent mixed function oxidase P450 system. The action of the
CYP4A family (arachidonic acid /-1 oxygenase activity) metabolism
in the kidney has been related to hypertension (Laniado-Schwartzman et
al., 1996; Makita et al., 1996) and the action of CYP2A, the
arachidonic acid epoxygenase, in the kidney may also be related to
disease states (Makita et al., 1996). Thus, these target enzymes could
become the targets of drugs of the future.The renal cytochrome P450 arachidonic acid system has been reviewed by
Laniado-Schwartzman and Abrahams (1992). A gene encoding a putative rat
kidney arachidonic acid epoxygenase was isolated from a kidney cDNA
library. Overexpression of this gene in COS-1 cells produced a protein
that catalyzed the NADPH-dependent metabolism of arachidonic acid with
similar specificity to P450 2C23 (Karara et al., 1993).A P450 isozyme, responsible for the oxygenation of polyunsaturated
fatty acids, has been well-documented in the kidney (Oliw, 1994).
Cytochrome P450K (CYP2C6) protein, catalyzing the hydroxylation of
various saturated fatty acids to the corresponding - and -1 hydroxy derivatives has been studied in rat kidney cortex by spectral and enzymatic methods (Ellin et al., 1972). The CYP4 gene family, expressed in rat kidney tissue,
includes isoforms that catalyze the /(-1) hydroxylation of
prostaglandin A (CYP4A7) (Kusunose et al., 1989) and fatty acids
(Imaoka et al., 1990b). Members of this family of CYP4A proteins have
been shown to be induced in kidney by peroxisome proliferators such as
di-(2-ethylhexyl)phthalate (Okita et al., 1993). In the rat kidney
CYP4A1 mRNA was induced by methylclofenapate (Bell et al., 1992) and
CYP4A2 mRNA was induced by dehydroepiandrosterone, an adrenal steroid
that is a peroxisome proliferator at high dosages (Webb et al., 1996).
b. TOXIN BIOTRANSFORMATION.
The biotransformation of
many toxins by P450 enzymes has been shown to occur in the kidney.
Renal microsomal cytochrome P450 was induced by xylene in the rat
kidney and studied as the O-deethylation of 7-ethoxyresorufin (Toftgard
and Nilsen, 1982). Enzyme assays and immunoblots were used to
demonstrate that dietary exposure to Aroclor 1254, a PCB, induced P450
1A2 (Beebe et al., 1995) whereas exposure to the pesticide, Fenarimol,
induced CYP 1A1 (Paolini et al., 1996).Not all toxic agents stimulate kidney P450 enzymes. The mutagenic
compound, 3-chloro-4-(dichloromethyl)-5 hydroxy-2(5H)-furone (MX) has
been found in chlorinated drinking water and shown to inhibit kidney
EROD (7-ethoxyresorufin-O-deethylase) activity. However, note that MX
induced UDP glucuronosyltransferase activity in kidney (see
glucuronidation section). Studies have shown tissue specific expression of dioxin induced P450
enzymes. Form 6 (CYP1A1 protein in rabbit) was found to be induced by
dioxin (TCDD) in rat kidney, whereas form 4 (CYP1A2 in humans) was
found to be localized in the rabbit liver as measured by enzymatic
assay (Liem et al., 1980). Using more sensitive immunohistochemistry, it was found that P-450 isoforms 4 and 6 stained
proximal tubules and endothelium intensely after TCDD treatment. The aromatic hydrocarbon receptor is a small cytoplasmic protein
required for the induction of CYP1A1 at the transcriptional level. This
protein has the highest affinity for TCDD and is sometimes called the
Dioxin inhibitor. (Parkinson, 1996). The general action of the aromatic
hydrocarbon receptor and it's localization in the kidney has been
reported by Ioannides and Parke (1990). In rabbit kidney of untreated animals it was found that forms 2 and 3 were localized to proximal tubules (Dees et al., 1982). In addition,
the P450 gene family, P450 1A1 has been found in kidney tissue after
induction with TCDD (Gonzalez, 1989).
c. SEX HORMONES.
As in other organs, sex related
expression and metabolism of various xenobiotics and endogenous
substrates by P450 enzymes have been shown in the kidney (Hawke and
Welch, 1985; Hu et al., 1993). Renal P450 enzymes have been induced
both in males or testosterone treated females (Williams et al., 1986)
and by estrogen (Liehr et al., 1987). Inducers such as 3-MC, PB, and
purazole changed induction profiles of CYP2A by significantly
increasing 7 
-hydroxylase activity in male kidney microsomes,
whereas only PB increased activity in females (Hoivik et al., 1995;
Pelkonen et al., 1994). Male specific induction of the gene encoding P450 4A2 as tested by
Northern blot analysis after treatment with the peroxisome proliferator, clofibrate, has been reported in the rat kidney (Sundseth
and Waxman, 1992). Administration of androgens to female mice changed
the mouse kidney pattern of expression of P450 enzymes from female to
male in 8 days. Male mice missing the androgen receptor were not
responsive to testosterone and maintained the female P450 kidney
distribution. (Henderson and Wolf, 1991). CYP4A2, a P450 isozyme found
in greater abundance in female rat kidney, was also induced by growth
hormone under certain conditions (Imaoka et al., 1992).
d. FASTING, OBESITY, EXERCISE, AND DIABETES.
The P450
content/g of kidney was increased by 50% over that of controls in the
obese overfed rat (Corcoran and Salazar, 1988). Starvation has been
shown by enzyme assay, spectrophotometric methods, and Western blots
(Imaoka et al., 1990b) to increase activity of CYP4A2 (P450 K-5)
extending early work showing starvation increased amounts of P450 and
laurate--oxidation activity in rat kidney microsomes (Hasumura et
al., 1983; McMartin et al., 1981). In addition, exercise has been
demonstrated to increase renal microsomal P450 by up to 60% in male
rats and age to reduce it (Piatkowski et al., 1993).In rats with streptozotocin (STZ)-induced diabetes, the P450 content
was reduced by 50% (Del Villar et al., 1995). P450 2EI, 4A2, and 4A8
(K-4) in renal microsomes were induced by diabetes along with and
-1 hydroxylation activity (Shimojo et al., 1993). It is possible
that although total P450 content may decline, specific P450's may
increase in STZ-induced diabetes.
B. N-Oxidation (Flavin-Containing Monooxygenases)
Flavin containing monooxygenases (FMOs) are found in liver, kidney, and lung and can oxidize the nucleophilic nitrogen, sulfur, and phosphorus heteroatom of a variety of xenobiotics. They require NADPH and O2 and catalyze some of the same reactions as cytochrome P450. These are mostly detoxication reactions, and metabolites produced generally result from the chemical reaction between a peracid or peroxide. FMO plays a role in the N- and S-oxygenation of numerous xenobiotics.
FAD is reduced by NADPH and oxidized NADP+ remains bound to the enzyme, which then binds oxygen producing a relatively stable peroxide. During oxygenation, the 4a-hydroperoxyflavin is converted to 4a-hydroxyflavin and the flavin peroxide oxygen is transferred to the substrate.
cDNAs for five different FMOs (FMO1, FMO2, FMO3, FMO4, FMO5)
have been cloned and sequenced. Each of these genes has been mapped to
the long arm of chromosome 1. The open reading frames deduced from the
DNA sequence of FMO1, 2, 3, and 5 contain between 532 and
535 amino acid residues and the calculated molecular mass is
approximately 60 kDa. FMO 4 is believed to encode 25 more
amino acid residues. Each of these genes is expressed in a species and tissue specific manner in humans and other mammals. The kidney of
mouse, rat, and human contains relatively high levels of FMO1, and FMO3
is high in the mouse and rat but not in the human kidney (Dolphin et
al., 1991; Parkinson, 1996). The forms of FMO are distinct gene
products with different physical properties and substrate
specificities. Human FMOs 1 and 3 have been expressed in bacterial and
insect systems, and the proteins found to be functionally active in
catalyzing the N-oxidation of N-ethyl-N-methylaniline and pargyline
(Phillips et al., 1995).
Many basic drugs, such as benadryl, imipramine, chlorpromazine,
nicotine, morphine, methaqualone, methadone, and meperidine, form
N-oxides. The chicken kidney was found to produce 7.2 µmol/hr/g kidney of trimethylamine oxide from trimethyl amine in vivo (Acara et
al., 1977). The same metabolism in chicken liver homogenates occurred
at a rate of 9.3 µmol/hr/g liver (Baker et al., 1963). After
meperidine perfusion of the isolated rat kidney, meperidine N-oxide was
identified by GC/MS as the major renal metabolite (Acara et al., 1981).
Vickers et al. (1996) found that N-oxidation was the major renal
biotransformation pathway for the 5HT3
antagonist, tropisetron. Although the overall contribution to
tropisetron metabolism was very small, 2 to 12 pmol/hr/mg slice for
human rat and dog kidney were comparable to human and rat liver (but
not dog). In the kidney, the only metabolite formed of imipramine was
its N-oxide (Lemoine et al., 1990). The kinetic analysis indicated an
affinity of 7 mM for human liver microsomes versus 0.3 mM in kidney.
C. Alcohol Oxidation
The principle route of elimination of alcohol is by oxidation to the aldehyde and subsequently to the carboxylic acid. Alcohols can also be directly conjugated with glucuronic acid and metabolized by a microsomal P450 enzyme. Although 90% of ethanol metabolism occurs in the liver, the enzyme is ubiquitous and renal metabolism also plays a role in elimination.
Alcohol dehydrogenase (ADH) (E.C. 1.1.1.1) is a cytoplasmic
NAD+ dependent zinc metalloenzyme that catalyzes
the reaction oxidizing an alcohol to an aldehyde and reduces
NAD+ to NADH. At this time, the human ADH family
consists of seven genes, which have evolved from a common ancestral
gene. The genes encode proteins belonging to one of five classes of ADH
isoenzymes based on structural and kinetic features. Class I (ADH1,
ADH2, ADH3) has a low KM for ethanol
and is sensitive to inhibition by pyrazoles. Classes II (ADHP) and III
(ADH5) have a higher KM for ethanol,
greater affinity for long chain alcohols, and are insensitive to
pyrazole inhibition. Class IV (ADH7), isolated from rat stomach, has
enzyme characteristics of class II but substantial structural
differences (Pares et al., 1992). Class V (ADH6) has been described in
liver and stomach (Yasunami et al., 1991).
Kidney ADH has been studied in several species (Moser et al., 1968).
Five major isozymes were isolated from various tissues in baboons, with
the kidney extract showing the highest activity of Class I isozymes
termed ADH 1 and ADH 2 (Holmes et al., 1986). The specific activity of
ADH from kidney extract with 5 mM ethanol as substrate was
476 nmol/min/g tissue, roughly one-third that seen in liver extract.
ADH mRNA was found to be present in the inner cortex and medulla of
kidneys from female Wistar rats (Qulali et al., 1991). Treatment with
estradiol induced ADH mRNA resulting in a three-fold increase in ADH
activity. ADH activity of liver was 5 times that of kidney but showed
no induction with estradiol. Subsequent studies localized
estradiol-induced ADH mRNA only to kidney tubule cells and further
elucidated the role of hormones in the control of rat kidney ADH
(Qulali et al., 1993). Fasting, hyperthyroidism, and treatment of male
rats with estradiol increased ADH activity. Androgens were found to
induce ADH mRNA in mouse kidney (Felder et al., 1988; Tussey and
Felder, 1989; Watson and Paigen, 1990) and although androgen treatment
caused a difference in the transcription rate of mRNA in the kidney,
liver ADH level was controlled posttranscriptionally.
D. Aldehyde Oxidation
Aldehydes are produced as intermediates in many biological
reactions. The most common source of aldehyde in humans is acetaldehyde formed from the metabolism of ethanol. In addition, aldehyde formation may result from biogenic amine metabolism, amino acid metabolism, and
lipid peroxidation of polyunsaturated fatty acids (Ambruziak and
Pietruszko, 1993).
Aldehydes may be oxidized to their corresponding carboxylic acid by
enzymes such as aldehyde dehydrogenase (ALDH) (E.C. 1.2.1.3), aldehyde
oxidase, and xanthine oxidase. ALDH activity in the kidney was first
described by Deitrich (1966). The overall activity of ALDH in the rat
kidney varies from 20 to 80% of that in rat liver (Deitrich, 1966;
Vasilou and Marselos, 1989; Dipple and Crabb, 1993). Because proximal
tubule cells contain cytochrome P450 and ADH, the cells have the
potential to oxidize a variety of compounds to aldehydes that are
potential cytotoxins. The presence of ALDH in these cells is thus
beneficial.
Three major classes of ALDH (E.C.1.2.1.3) containing several isozymes
have been described. Class 1 are cytosolic ALDHs that have been
localized primarily in the liver and exhibit broad substrate specificity and a low KM with
acetaldehyde as a substrate. Class 2 ALDHs are mitochondrial enzymes
that are present at significant levels in human (Agarwal et al., 1989),
opossum (Holmes et al., 1991), rat (Dipple and Crabb, 1993), and mouse
(Ront et al., 1987) kidney, as well as the liver. Class 2 ALDHs also
show a low KM for acetaldehyde
and are active in aliphatic and biogenic amine metabolism. Class 3 ALDHs include the major corneal/stomach ALDH with a high
KM for acetaldehyde and have
not been described in the kidney.
The genomic structure of the gene encoding human class 1 ALDH protein
(Hsu et al., 1989) and class 2 ALDH protein (Hsu et al., 1988) have
been described. Each has approximately 50 kb and consists of 13 coding
exons separated by 12 introns. Human class 3 ALDH has also been cloned
and sequenced. Recently several additional human ALDH genes have been
identified but have not yet been assigned to gene classes. In
particular, ALDH7 cDNA was cloned from human kidney tissue
(Hsu et al., 1994). Information on ALDH genes may be obtained from
the Internet at the "Vasilou Laboratory Home Page"
(http://www.uchsc.edu/sp/sp/alcdbase/alcdbase.html).
An isozyme termed ALDH5 was found to be present in both cytosolic and
mitochondrial fractions of many opossum organs including the kidney
(Holmes et al., 1991). The isozyme ALDH4, a mitochondrial enzyme with a
high KM was found to have
significant activity in kidney (Agarwal et al., 1989; Holmes et al.,
1991). On purification, it was found to be identical with
glutamate-semi-ALDH (E.C. 1.5.1.2) (Forte-McRobbie and Pietruszko,
1986). Isozymes have been shown to vary in time of appearance during
development (Ront et al., 1987). A rat kidney ALDH isozyme that
catalyzes the oxidation of retinol to retinoic acid has been isolated
(Labrecque et al., 1995) and the cDNA encoding this protein has been
cloned (Bhat et al., 1995).
Subcellular fractionation of proximal tubule fragments from rabbit
kidney using propionaldehyde as a substrate showed ALDH activity to be
bimodally distributed in the mitochondrial and cytosolic fractions.
Kinetic characteristics suggested the presence of two isoenzymes
(Hjelle et al., 1983).
3-MC induced ALDH activity in rat kidney using benzaldehyde/NADP as
substrate but no change was seen after PB treatment (Vasilou and
Marselos, 1989). It appears that the pattern of ALDH induction is
dependent on the inducer.
E. Oxidative Deamination (Monoamine Oxidase)
Monoamine oxidase (MAO) amine:oxygen oxidoreductase (deaminating
flavin-containing E.C.1.4.3.4.) catalyzes the oxidative metabolism of
amines. MAO is tightly associated with the outer mitochondrial membrane. The reaction catalyzed by MAO consists of reductive and
oxidative half reactions. In the reductive half reaction, the amine
substrate is oxidized and the covalently attached FAD reduced to the
hydroxyquinolone. In the second half-reaction, the FAD is reoxidized by
oxygen with formation of
H2O2 and an aldehyde
(Weyler et al., 1990). The sum of the MAO partial reactions is:
|
(2) |
There are two isoforms of MAO, designated A and B, which are widely
distributed in mammalian tissues and function to breakdown not only
biogenic amines but a wide variety of amines including aliphatic,
aromatic, primary, secondary, and tertiary amines. The two forms were
originally demonstrated through selective inhibition by clorgyline
(MAO-A) (Johnston, 1968) and deprynel (MAO-B) (Knoll and Magyar, 1972).
Subsequently, they have been distinguished by differences in substrate
preference (Lyles and Shaffer, 1979), tissue and cellular distribution
(Weyler et al., 1990), immunological properties (Denny et al., 1983),
and most recently determination of nucleotide sequences of cDNA (Bach
et al., 1988). cDNA cloning of human liver monoamine oxidase A and B
has determined that they are derived from separate genes. The MAO-A and
MAO-B human genes are located next to each other on the human X
chromosome. The A and B forms have subunits with molecular weights of
59.7 and 58.8 kDa, respectively with 70% sequence identity. The
obligatory cofactor FAD is covalently bound to cysteine in the same
pentapeptide sequence in both isoforms. The genes for monoamine oxidase
A and B have identical exon-intron organization, suggesting a common ancestral gene (Grimsby et al., 1991).
The kidney contains high concentrations of both MAO-A and -B. Most of
the activity has been shown to be in tubular cells and the enzyme is of
particular importance in the metabolism of amines filtered by the
kidney (Fernandes and Soares-da-Silva, 1990).
Table 2 shows the kinetic parameters of
MAO from homogenates of human and rat kidney. In human kidney, the
similar activities toward 5-hydroxytryptamine and phenylethylamine
suggest that differences in Vmax are caused by
differences in concentration of the enzyme (Fernandes and
Soares-da-Silva, 1992). The activity of MAO-A is similar in cortex and
medulla, whereas that of MAO-B is higher in the cortex. Studies in
rabbit renal proximal tubule using Western blot analysis and enzyme
assays show MAO-B to be the predominant isoform. This isoform holds the
I2 imidazoline binding site, a regulator of
MAO (Gargalidis-Mondanase et al., 1997). In rat tissue, MAO-A is the
predominant form. The MAO activity of human kidney is approximately
one-third that of liver (Vogel et al., 1983).
|
It has been demonstrated that in rat renal slices a substantial amount
of newly formed dopamine is deaminated to 34-dihydroxyphenylacetic acid
in renal tubular cells (Fernandes and Soares-da-Silva, 1990). The
effect of aging on MAO activity in the kidney has been studied, with
little change found in rabbits or mice (Feldman and Roche, 1978) but a
small decrease in MAO-A and MAO-B activity was seen in aging rats (Lai
et al., 1982).
F. Aldehyde and Ketone Reduction
Aldehydes and ketones are widely distributed and have several biological functions. In addition to ADH, there are several enzymes in the aldo-keto reductase family that may participate in the metabolism of aldehydes and ketones in the kidney. Aldose reductase (E.C. 1.1.1.21), aldehyde reductase (E.C. 1.1.1.2), and carbonyl reductase (E.C. 1.1.1.184), also referred to as ketone reductase, are members of this enzyme family that are found in relatively high amounts in the kidney. These enzymes reduce aldehydes and ketones to their corresponding alcohols. Aldose reductase has been found to metabolize only endogenous compounds in the kidney. Therefore it will not be discussed further in this review.
1. Aldehyde reductase.
The aldehyde reductases are members of
a superfamily of NADPH-dependent reductases that contribute to the
metabolism of certain carbonyl compounds (Bohren et al., 1989). The
enzymes are of monomeric structure and have broad substrate sensitivity
in reducing xenobiotics and naturally occurring carbonyl compounds. The
enzymes are widely distributed with kidney having the highest activity
in most species (Bosron and Prairie, 1973), and a concentration of up
to 0.5% of the total protein in tissue homogenates. Aldehyde reductase was first purified to homogeneity in pig kidney (Bosron and Prairie, 1972) and has been demonstrated to be active in the reduction of
p-nitrobenzaldehyde, indole-3-acetaldehyde,
DL-glyceraldehyde, and D-glucuronate (Flynn,
1986). The cDNA of human aldehyde reductase has been cloned and
sequenced and encodes a protein with a deduced Mr of 37 kDa.
). Aldehyde reductases are
characterized by inhibition by PB (Flynn, 1982).
2. Ketone reductase.
Ketone reductase (also known as carbonyl
reductase) is another member of the aldo-keto reductase superfamily
that may reduce certain unoxidized carbonyl substances. Aromatic,
acyclic, and unsaturated ketones may be reduced to free or conjugated
alcohols. The best substrates are quinones (Wermuth et al., 1986). The
various ketone reductases have common features such as ubiquitous
tissue distribution, primarily cytosolic localization, and preference for NADPH as a coenzyme.
). The structure and gene sequence of human carbonyl reductase
has now been identified and found to be a member of the short-chain
dehydrogenase family (Wermuth et al., 1988).
In the human kidney, carbonyl reductase was found to be localized to
the proximal convoluted and straight tubules (Wirth and Wermuth, 1992).
The enzyme was found to be identical with a prostaglandin 9-ketoreductase from human and pig kidney (Shieber et al., 1992).
The enzyme purified from rabbit kidney reduces several drugs with a
ketone group, such as acetohexamide, befunolol, metapyrone, levobunolol, daunorubicin, haloperidol, moperone, trifluperidol, and
loxoprofen, along with several other aldehydes and ketones (Imamura et
al., 1993; Higuchi et al., 1993). Dihydromorphinone reductase has been
isolated from chicken and rabbit kidney (Roerig et al., 1976), warfarin
reductase from human, rabbit, and rat kidney (Moreland and Hewick,
1975), and oxisuran, daunorubicin, and metapyrone reductase from rabbit
and human kidney (Ahmed et al., 1979). The specific activities of renal
reductase toward these substrates was generally high, second only to
liver in terms of tissue distribution (Ahmed et al., 1979). Although
generally found to be cytosolic enzymes, the microsomal fraction in
mouse, rat, and guinea pig kidney had significant metapyrone reductase activity (Opperman et al., 1991). The enzymes have been found to be
inhibited by quercetin (Felsted and Bachur, 1980) and by nonsteroidal
drugs such as indomethacin (Higuchi et al., 1994).
3. Other.
Other enzymes that have been shown to be involved in
the reduction of xenobiotic carbonyl compounds in the kidney are
dihydrodiol dehydrogenases and 11--hydroxysteroid dehydrogenase.
Dihydrodiol dehydrogenase (E.C. 1.3.1.20) catalyzes the reduction of
dicarbonyl compounds and some aldehydes in the presence of NADPH (Hara
et al., 1989) and plays a role in the detoxification of endogenous ketoaldehydes such as methylglyoxal and 3-deoxyglucosone. Dimeric dihydrodiol dehydrogenase has been isolated from monkey kidney (Nakagawa et al., 1989). 11--hydroxysteroid dehydrogenase has been
assayed in mouse kidney and displays xenobiotic carbonyl reductase
activity toward the drug metapyrone as well as endogenous glucocorticoid 11-B-oxidoreduction (Maser et al., 1994).
G. Hydrolysis Mechanisms
1. Ester and amide hydrolysis/carboxylesterase and amidase.
Carboxylesterases/amidases (E.C. 3.1.1.1) catalyze hydrolysis of
carboxylesters, carboxyamides, and carboxythioesters, as seen below in
equations 3 to 5, respectively (Heymann, 1980). The specificity of the
carboxylesterase/amidase action depends on the nature of R, R', R".
|
(3) |
|
|
(4) |
|
|
(5) |
|
).
Because proteins classified as carboxylesterases have also been shown
to be potential amidases, and vice versa, we will refer to this class
of enzymes simply as carboxylesterases. As with several other enzymes,
there are differences in classification schemes. In genetic
nomenclature, each esterase is termed "Es" followed by a number.
However, this is not available for most of the enzymes discussed in
this review. A classification scheme introduced by Aldridge (1953) is
based on the inhibition of certain carboxylesterases by paraoxon. The
A-esterases (arylesterases) act preferentially on aromatic esters, use
paraoxon as a substrate, and are inhibited by 4-chloromercuribenzoate
or Hg2+. The B-esterases (carboxylesterases or
serine hydrolases) have aliphatic esters as the preferred substrate,
are inhibited by paraoxon, and Hg2+ is without
effect. The C-esterases (acetylesterases) act on acetyl esters, are not
inhibited by paraoxon, and are activated by 4-chloromercuribenzoate or
Hg2+ (Bergmann et al., 1957). Although these
three classes (along with cholinesterase) have been described in renal
tissue, the best studied in the kidney are the B-esterases (Ecobichon
and Kalow, 1964), where there are relatively high amounts localized predominantly to the proximal tubule (Wienker et al., 1973; Bocking et
al., 1976; Yan et al., 1994).
Ecobichon and Kalow (1964) first described aliesterase and
acetylesterase activities present in human kidney. In further studying the species distribution of renal carboxylesterase activity, Ecobichon (1972) found that horse, dog, ox, guinea pig, and female mouse kidney
tissue homogenates had activity comparable with that found in human
kidney, approximately 10% of that in liver. Cat, rat, and male mouse
kidneys had activities comparable with that seen in liver with
-napthylacetate as substrate.
Carboxylesterases have been purified from kidneys of different species.
A trimeric B-esterase with a Mr of approximately 160 kDa was purified
from pig kidney (Heymann and Iglesia, 1974). A testosterone-dependent
carboxylesterase termed esterase-9A, with a Mr of 45 to 51 kDa was
purified from mouse kidney (Goeppinger et al., 1978), which was later
shown to be a component of the ES-20 trimer (DeLooze et al., 1985).
A carboxylesterase was purified from rat kidney, which was found to
have a Mr of approximately 60 kDa and primarily localized to the
microsomal fraction, although activity was also found in the cytosol.
Maximum activity toward methylbutyrate occurred at a concentration of
200 mM at a pH of 8. This carboxylesterase catalyzed the
hydrolysis of mono-acylglycerols and short-chain triacylglycerols but
not long-chain triacylglycerols (Tsujita et al., 1988).
A rat kidney decarboxylase, termed hydrolase B, has been cloned and
sequenced and found to be indistinguishable from rat liver hydrolase B
(Yan et al., 1994). Immunocytochemical studies have shown the enzyme to
be localized to the proximal tubule. It catalyzes the hydrolysis of
p-nitrophenylacetate with low affinity and is insensitive to
inhibition by phenylmethylsulfonyl fluoride. The active site had the
catalytic triad composed of Ser203,
His448, and Asp97, or
Glu228 (Morgan et al., 1994). Palmitoyl-coenzyme
A hydrolase was subsequently found to have the same N-terminal amino
acid sequence as hydrolase B (Tsujita and Okuda, 1993).
Carboxylesterase activity is found in the microsomal fraction of kidney
homogenates (Ashour et al., 1987; Morgan et al., 1994; Yan et al.,
1994). Electron microscopy of proximal tubule kidney cells showed that
most of the B-esterase activity is localized in the endoplasmic
reticulum, although some is seen on the periphery of the mitochondria.
However, another study showed B-esterase localized to the mitochondria
in mouse kidney (Bocking et al., 1976). Low levels of A-esterase
activity have been demonstrated in the microsomal fraction of rat
kidney (Pond et al., 1995).
The substrate specificity of kidney carboxylesterase has principally
been studied using simple aliphatic esters, such as methyl-butyrate (Tsujita et al., 1988) and phenol esters such as
p-nitrophenyl acetate (Ecobichon, 1972). Acetylsalicylic
acid esterase activity has been demonstrated in rat kidney (Ali and
Kaur, 1983).
The physiological regulation of kidney carboxylesterase appears to be
similar to that of the liver. There are several testosterone-dependent esterases in male mouse kidney. Using p-nitrophenylacetate
as a substrate, carboxylesterase activity was induced in rat kidney by
the polycyclic hydrocarbons BP and 3-MC (Nousainen et al., 1984).
2. Epoxide hydrolysis. The epoxide hydrolases are a family of enzymes that hydrolyze various epoxides to their corresponding diols. There are four known principal epoxide hydrolases: microsomal epoxide hydrolase (mEH), cytosolic (soluble) epoxide hydrolase (sEH), cholesterol epoxide hydrolase, and leukotriene epoxide hydrolase.
Aromatic and olefinic compounds may be metabolized by MFOs to reactive electrophiles such as epoxides. These epoxides can be formed as metabolites of drugs such as cyproheptadine, carbamazepine, and protriptyline. The epoxides can then (a) rearrange to alcohols; (b) be metabolized by glutathione transferase; or (c) be metabolized to transdihydrodiols by mEH (E.C.4.2.1.63). The latter product is usually nontoxic but may serve as a precursor to more reactive dihydrodiol epoxides. mEH plays a more important role in the metabolism of xenobiotics. The mEH is in the same compartment as the epoxide producing monooxygenase system. It catalyzes the conversion of highly reactive arene and alkene oxides to the less reactive dihydrodiols by cleavage of the oxirane ring. The enzyme appears to be predominantly localized to the endoplasmic reticulum. The best substrates are oxiranes with 1 to 2 hydrophobic constituents. The liver microsomal enzyme system has been sequenced (Heinemann and Ozols, 1984; Porter et al., 1986) and well characterized as to
substrate specificity as well as enzyme properties and kinetics (Wixtrom and Hammock, 1985). Constitutive expression of mEH RNA was
observed in rabbit kidney (Hassett et al., 1989). In addition to the
mRNA characterized for one form of mEH in rat (mEHb), two other mEHb mRNAs that differed at the 5' end were isolated
in rat liver that were the result of alternative mRNA splicing (Honscha et al., 1991), but only one mRNA was expressed in kidney. It is believed that all of the mRNAs encode the same protein. mEH has been
found in kidney from rat, mouse, and hamster (Oesch et al., 1977; Oesch
and Schmassman, 1978) and localized to proximal tubules and collecting
ducts (Tsuda et al., 1987; Sheehan et al., 1991). In human kidney
immunohistochemical studies demonstrated mEH to be localized primarily
to proximal and distal tubule, but there was also staining in the
collecting ducts and vascular endothelial cells (McKay et al., 1995).
mEH activity in human kidney was found to be present at 5% that in
liver (Pacifici et al., 1988a).
mEH is commonly increased by treatment with xenobiotics. In rat kidney,
where a control level of 1.2 µg/mg protein of mEH was found, there
was a two-fold increase after treatment with clofibrate (Moody et al.,
1987). Treatment of rats with thiazole caused a six- to eight-fold
increase in kidney mEH mRNA levels with a two-fold increase in mEH
protein (Kim et al., 1994). Induction of rat proximal tubule epoxide
hydrolase by administration of lead acetate has been shown in the
absence of induction of the hepatic enzyme (Sheehan et al., 1991).
Whole kidney EH mRNA in rat was found to rise postpartum but remained
stable after 35 days of age (Simmons and Kasper, 1989). As opposed to
liver where there were age and gender related changes in mEH
expression, microsomes from rat kidney showed no age-dependent change
in either sex (Kim and Kim, 1992).
sEH has differing substrate specificity than the microsomal enzyme.
Many compounds that are poor substrates for mEH are good substrates for
sEH. These substrates include epoxides derived from polycyclic aromatic
compounds, unsaturated fatty acids, and transsubstituted styrene
derivatives. Poorly metabolized epoxides are the best inhibitors, and
induction studies suggest that sEH is peroxisomal in origin.
The cDNA encoding rat liver sEH has been characterized and expressed in
Escherichia coli (Knehr et al., 1993). Human liver sEH cDNA encoding the sEH protein has also been isolated
(Beetham et al., 1993). The human gene EPHX2, encoding
the sEH protein has been localized to chromosome 8 and its structural
organization determined. The gene consists of 19 exons and is
approximately 40 kb (Sandberg and Meijer, 1996).
sEH has been detected in rat and mouse kidney tissues. In the rat, sEH
activity using transstilbene oxide and transethylstyrene oxide as
substrates was greater in kidney than liver (Schladt et al., 1986). The
hypolipidemic agent, clofibrate, increased sEH two-fold.
sEH has been detected in mouse kidney (Kaur and Gill, 1985) at a level
two-fold less than that of the liver enzyme. sEH activity was greater
in liver than in kidneys of male and female mice and shown to increase
with age (Pinot et al., 1995). There was greater activity of sEH in
both the liver and kidneys of adult males than females and this sexual
dimorphism was more pronounced in the kidneys (283% higher) than in
the liver (55% higher). The same study showed that testosterone and
clofibrate independently regulate sEH activity in vivo and that kidneys
and liver respond differently to these agents.
Cholesterol 56-oxide hydrolase is a microsomal enzyme which catalyzes
the hydroxylation of several steroid 56-oxides by trans-addition of
water (Guenther, 1990). It has been identified in rat kidney.
Leukotriene A4 hydrolase catalyzes the hydrolytic cleavage
of the LTA4 oxirane ring. It is a cytosolic enzyme that has
been found to have significant activity in guinea pig kidney (Izumi et
al., 1986).
| |
III. Phase II: Synthetic Conjugation Pathways |
|---|
|
TopPreviousNextReferences
|
|---|
In conjugation reactions, a xenobiotic is linked to an endogenous moiety through a functional group that may be present on the original drug or which results from a (phase I) reaction of oxidation, reduction or hydrolysis. In many conjugation reactions a proton, present in a hydroxyl, amino or carboxyl group, is replaced by the conjugating agent. In general, conjugated metabolites are highly water soluble and have no pharmacological activity. Glucuronidation, sulfation, acetylation and conjugation with glutathione or amino acids form the major phase II reactions.
A. Glucuronidation
One of the major routes of inactivation and elimination of
xenobiotics, as well as certain endogenous compounds, is
conjugation with uridine diphosphate (UDP) glucuronic acid (UDPGA).
This reaction, catalyzed by UDP-glucuronyltransferases (UGT) (E.C.
2.4.1.17), results in compounds that generally are less biologically
active and more polar. The latter characteristic facilitates their
excretion in bile and urine (Siest et al., 1987). Glucuronidation is an Sn2 reaction in which a nucleophile acceptor group on the substrate attacks an electrophilic C-1 atom of the glucuronic acid group. Thus,
many electrophilic groups such as hydroxyl, carboxyl, sulfhydryl, or
phenol can serve as an acceptor. N-glucuronides may be formed by
certain nitrogen containing groups such as tertiary or aromatic amines.
Esterification of the hemiacetyl hydroxyl group of glucuronic acid to
organic acids forms acyl or ester glucuronides. The acyl glucuronides,
unlike glucuronides formed with phenols and alcohols, have a great
susceptibility to nucleophilic substitution and intramolecular
rearrangement (Faed, 1984). Although it has been thought for some time
that phase II metabolites of drugs, such as the O- or N-glucuronides,
are rapidly excreted, this is not true for the reactive acyl
glucuronides (Spahn-Langguth and Benet, 1992). Nonsteroidal
antiinflammatory drugs of the aryl-alkyl class with a high incidence of
adverse drug reactions including nephritis and acute renal failure were
removed from the market (e.g., benoxaprofen, indoprofen, alclofenac,
ticrynafen and ibufenac). It has been proposed that the formed acyl
glucuronides acting as electrophiles and reacting with sulfhydryl and
hydroxyl groups of cell macromolecules might be responsible for this
toxicity (Spahn-Langguth and Benet, 1992).
Glucuronidation requires a sufficient supply of UDPGA and its
concentration in the cytosol may determine the transferase activity. This may be more critical in extrahepatic tissues than in the liver.
The concentration of UDPGA in the kidney has been found to be
one-fifteenth that of liver in human tissues (Cappiello et al., 1991)
and also substantially lower than in livers of guinea pig, rat, and
mouse (Wong, 1977).
Once glucuronidation has occurred, whether in the liver, kidney, or
other organs, the glucuronide conjugates are excreted either in bile or
urine. The renal clearance of glucuronides has been studied in several
animal species. Active tubular secretion has been demonstrated for
certain glucuronide conjugates, such as those of catecholglucuronides
in the chicken (Quebbemann and Rennick, 1969) and 1-naphtholglucuronide
in the isolated perfused kidney of the rat (Redegeld and Noordhoek,
1986).
As with other drug metabolizing enzymes in the kidney, UGTs can be
activated and induced by factors altering the metabolic state of the
animal. For example, kidney microsomes of STZ diabetic rats have been
shown to have a lower UGT substrate efficiency that was not reversed by
insulin treatment (Del Villar et al., 1995).
Extrahepatic glucuronidation can easily be demonstrated in whole animal
experiments (Cassidy and Houston 1980; Mazoit et al., 1990; Gray et
al., 1992; and Vree et al., 1992). Much of this extrahepatic metabolism
is assumed to occur in the kidney. This review will focus on examples
of UGTs that can definitely be localized to the kidney.
1. Isoforms.
Molecular probes have recently been developed
that have helped to characterize the large number of isoforms in the
UGT gene family. Over 25 UGT cDNAs have been cloned and sequenced
(Burchell, 1994). The human hepatic UGT cDNAs cloned have been
classified into two families, UGT1 And UGT2. The product of the
phenol/bilirubin UGT1 gene has many isoforms and is active in the
glucuronidation of a variety of drugs. The product of the steroid/bile
acid UGT2 gene catalyzes the glucuronidation of steroids, fatty acids,
and certain carboxylic drugs. Further development in this area will permit a unified nomenclature structure.
; Burchell et
al., 1994).
Isozymes have also been distinguished on the basis of physiological
criteria, by induction studies, and more recently by purification. As
mentioned above, the principle enzyme forms involved in xenobiotic transformations have been denoted "GT1" (induced by 3-MC, TCDD, Aroclor 1254, and -NF) and "GT2" (induced by PB). Coughtrie and colleagues (1987) purified rat kidney UGT, which was active toward 1-naphthol, 4-nitrophenol, phenol, bilirubin, and estradiol. Activity was induced after treatment of rats with -NF but not after treatment with PB. Bilirubin UGT was specifically induced after treatment with
clofibrate.
Differences in renal UGT isoforms between species are clearly apparent.
For example, renal glucuronidation of morphine is found in microsomes
from human fetal (Pacifici and Rane, 1982) and adult (Yue et al., 1988)
kidney but not in rat kidney microsomes (Rush and Hook, 1984; Koster et
al., 1986). Thus, human kidney contains the functional "GT2", not
found in the rat. Using recombinant UGT1A1, (R)-naproxen was found to
be a stereoselective substrate of rat UGT1A1 but not of the orthologous
human UGT1A1 (Mouelhi et al., 1993). Induction of UGT activity by TCDD,
as measured in kidney microsomes, has been shown to be species
specific. In rat kidney, UGT was induced five-fold, whereas in rabbit
and guinea pig kidney microsomes, no induction was seen (Hook et al.,
1975).
2. Substrates and kinetics.
The activity of UGT in kidney
microsomes has been found to be substrate dependent (Chowdhury et al.,
1985). Rates of glucuronidation of 1-naphthol and morphine are
comparable in human tissue but the lower concentration of UDPGA in
kidney provides evidence that the renal contribution to total
glucuronidation may be limited in vivo (Capiello et al., 1991). There
are a large number of xenobiotics as well as endogenous compounds that
have been shown to undergo glucuronidation in the kidney (table
3).
|
).
Bilirubin glucuronidation rate in rat renal microsomes was found to be
approximately one-half that of the liver in untreated control animals
(Chowdhury, 1985; Coughtrie et al., 1987). A comparison of formation of
codeine 6-glucuronide by Yue et al. (1990) showed that the rate for
human liver microsomes was 0.77 nmol/mg/min whereas that for kidney
microsomes was 14-fold less.
Kinetic studies of UGTs are difficult to compare because phospholipids
had differential effects on microsomal preparations isolated from rat
liver and kidney (Yokota et al., 1991). The activity of the hepatic
enzyme toward naphthol was increased eight-fold by
lysophosphatidylcholine but the renal activity increased only three-fold. Dilauroylphosphatidylcholine increased activity of the
hepatic transferase two-fold but reduced that of the renal enzyme.
3. Induction of renal glucuronyl transferase.
Most studies
demonstrating induction of this enzyme in the kidney have been
performed in the rat (table 4). Induction
of UGT isozymes of 54 kDa and 56 kDa by 3-MC or A1254 was demonstrated in renal as well as hepatic microsomes (Koster et al., 1986). This
increase in protein correlated with an increase in glucuronidation capacity for "GT1" substrates. Gel electrophoresis revealed protein bands of 54 and 55 kDa. In addition, immunoblot analyses with anti-rat
liver uridinediphosphoglucuronyl transferase (UDPGT) revealed
polypeptides of 56 and 54 kDa that catalyzed glucuronidation of
1-naphthol and bilirubin. Yokota and colleagues (1989) have isolated
UDPGT from rat kidney (termed "GT-2"), which immunochemically corresponds to a form of UDPGT ("GT-1") purified from rat liver. It
is inducible by 3-MC and has activity toward phenolic xenobiotics. In
addition, they found that UDPGT activity toward phenolic xenobiotics and serotonin was enhanced several-fold by treatment of the animal with
-NF. They purified this form and found it to be a 54 kDa protein
consisting of a polypeptide with high mannose oligosaccharide chains.
The NH2 terminal residues of this "GT-2" were found to differ by two residues in the final seven from the "GT-1" form. Kidney microsome UDPGT activity toward pNP was increased after induction by 3-MC but not by PB. An increase in kidney microsomal protein of 54 kDa, corresponding to GT-1, was recognized by
immunoblotting (Yokota and Yuasa, 1990). Salicylic acid induces
glucuronidation of o-aminophenol and catechol in the chicken kidney as
seen using whole animal SADR studies (Diamond et al., 1982) and
hexabromobiphenyl induces the glucuronidation of 4-methylumbelliferone
in mouse kidney (Aitio et al., 1972).
|
4. Localization.
With respect to localization within the
kidney, UGT activity is primarily limited to the cortical region
(Stevenson and Dutton, 1962; Rush and Hook, 1984), and the activity is
greatest in cells of the proximal tubule (Hjelle et al., 1986). Renal
UGT activity has been demonstrated in isolated tubule fragments (Fry et
al., 1978) and isolated tubule cells (Jones et al., 1979) as well as the microsomes obtained from homogenization of renal cortical tissue.
GT activity toward morphine has been demonstrated in human renal
medullary tissue but at approximately half the level of that seen in
the cortex (Yue et al., 1988). Because the proximal tubule cells are
exposed to the initial filtrate through the glomerulus, it would be
logical for them to play the primary role in xenobiotic conjugation.
Within the individual cells, the UDP glucuronyltransferases (UGTs) are
a family of membrane bound enzymes located in the endoplasmic reticulum. The enzyme, including the active site, is thought to be
primarily within the lumen of the ER (Mulder, 1992).
5. Relative contribution of renal glucuronidation.
Measurement
of tissue activities showed that after the liver, the highest activity
(one-third to one-half) of UDPGT is found in kidney (Krishna and Klotz,
1994). It is more difficult to determine the actual renal contribution
to glucuronidation in vivo. Using the SADR technique, renal conjugation
of pNP was studied in the chicken (Diamond and Quebbemann, 1981). Like
humans, the chicken excreted pNP almost entirely in the urine. A
minimum of 38% of pNP conjugation (sulfate and glucuronidation) was
nephrogenic in origin at an infusion rate of 100 nmol/min/kg. At a
20-fold higher infusion rate, the percentage of renal contribution to conjugation dropped markedly, indicating increased participation by
other organs.
,
1985). Extrahepatic conjugation of harmol was found to be greater than
that of the liver, but kidney localization for this activity was not
specifically demonstrated (Mulder et al., 1984).
B. Sulfation
In addition to being a major conjugation pathway for phenols, sulfate contributes to the biotransformation of xenobiotic alcohols, amines, and thiols. It is also important in the metabolism of endogenous compounds such as neurotransmitters and steroid hormones. The resulting compounds are generally less active, more polar, and more readily excreted in the urine.
Sulfate conjugation is a multistep process. Inorganic sulfate is inert and must first be converted to adenosine-5' phosphosulfate (APS) and then to an activated form, 3'-phosphoadenosine 5' phosphosulfate (PAPS) by the following reactions:
|
(6) |
|
(7) |
), but kidney cells synthesize significant amounts, with the concentration higher in the
cortex than in the medulla (Hjelle et al., 1986).
The reaction by which sulfotransferases catalyze the transfer of a sulfuryl group from PAPS to the acceptor molecule (i.e., phenol) is shown in the following reaction:
|
(8) |
|
), although the individual forms may not have been identified
there.
Sulfate conjugation is regulated by (a) the sulfate
concentration, (b) availability of inorganic sulfate, and
(c) the synthesis of PAPS. Studies on the sulfate
conjugation of 7-hydroxycoumarin by isolated kidney cells showed that
inorganic sulfate was the most effective precursor for PAPS formation,
but that cysteine, N-acetylcysteine, and glutathione could also be used
(Dawson et al., 1983).
Capiello et al. (1989) showed that the concentration of PAPS in human
kidney was 4.8 nmol/mg tissue, 21% that of the liver, and
sulfotransferase activity was 0.034 nmol/min/mg. The conjugation of
2-naphthol by the kidney proceeded at 2% that of the liver. The
reduced availability of PAPS in the kidney may reflect the small
requirements for this substrate.
Sulfotransferase enzymes are members of a gene superfamily that
includes phenol ST, hydroxysteroid ST, and flavonol ST. There are
currently five human cytosolic ST enzymes: three phenol STs, a hydroxy
steroid ST, and an estrogen ST. The cDNAs and genes have been cloned
for each of these (Weinshilboum et al., 1997) and their chromosomal
locations determined. At this time, 30 eukaryotic ST cDNAs have been
reported. An ST enzyme classification system has been devised based on
the primary amino acid sequence of the enzymes (Weinshilboum et al.,
1997). Most of the cloning experiments have been performed using liver
tissue. Recently, a cDNA of human ST, named SULT1C1, has been cloned
and dot blot analysis of mRNA indicated that this cDNA was expressed in
human kidney as well as other tissues (Her et al., 1997).
Overall, sulfate conjugation in the kidney, as well as in the liver,
plays a lesser role quantitatively than glucuronidation in the
metabolism of xenobiotics (Hjelle et al., 1986; Elbers et al., 1980;
Redegeld et al., 1988). However, for certain compounds, such as harmol,
renal sulfate conjugation predominates (Mulder et al., 1984). There has
been relatively little study of renal sulfate conjugation compared with
glucuronidation.
Sulfate of the steroids dehydroepiandrosterone and estrone, as well as
the compound pNP was described by Holcenberg and Rosen (1965).
Incubation of 17--estradiol with human renal slices produced estrone
sulfate and estradiol-3-sulfate metabolites (Mellor and Hobkirk, 1975).
Dehydroepiandrosterone sulfotransferase has been identified in the
human fetus (Barker et al., 1994). Sulfate of the -adrenoreceptor
agonist ritodrine was found to be substantially higher in human fetal
tissue than in adult kidney (Pacifici et al., 1993).
Pacifici et al. (1988b) demonstrated that sulfotransferase activity
using 2-naphthol as substrate was present in the cytosolic fraction of
human fetal as well as adult kidney. Activity in fetal kidney was twice
as high as that of liver whereas adult kidney activity was 15-fold less
than observed in the cytosolic fraction of adult liver. Naphthol was
sulfated (as well as glucuronidated) by rabbit kidney (Hjelle et al.,
1986). Incubation of human kidney cortex with biphenyl formed
4-hydroxyphenylsulfate at a rate one-tenth that of liver (Powis et al.,
1987). 1-naphthol was metabolized to the sulfate and glucuronide
conjugate in the isolated perfused rat kidney as well as guinea pig
tubule fragments (Redegeld et al., 1988; Schwenk and Locher, 1985).
Sulfotransferase activity in the kidney has been localized in cytosolic
as well as membrane fractions of rabbit proximal tubules (Hjelle et
al., 1986). Measurement of activity in homogenates of cortex and outer
medulla, as well as in isolated proximal tubules of rabbit, showed
greatest activity in the proximal tubule, which was 2.2-fold that of
the cortex.
Using the Sperber technique in chickens, Quebbemann and Anders (1973)
demonstrated renal tubule formation and excretion of sulfate (and
glucuronide) conjugates of phenol and pNP. When infused into the
saphenous vein at 1 nmol/min, 80% of the phenol and 50% of the pNP
that reached the kidney were excreted in the urine. All the excreted
phenol and pNP were identified as sulfate or glucuronide conjugates.
Using the SADR technique, renal sulfate and glucuronide conjugation of
pNP was studied in the chicken (Diamond and Quebbemann, 1981). pNP
sulfate was found to be the major urinary metabolite, and approximately
38% of the pNP sulfate was nephrogenic at an infusion rate of 100 nmol/min/kg. Renal sulfate conjugation of 1-naphthol and pNP has been
found to account for a minimum of 20% of the endogenously formed
conjugates excreted in the urine of the rat.
Sulfate conjugation contributed to paracetamol metabolism in the
isolated perfused kidney and hydroxybiphenyl conjugation in human
kidney (Pacifici et al., 1991a). The maximal rate of 4-MUF conjugation
as sulfate in kidney tubule fragments was 17% of that found in
isolated hepatocytes (Fry et al., 1978). Formation of acetaminophen
sulfate in isolated kidney cells was 5% that of liver, and was
unchanged by treatment of rats with 3-MC (Jones et al., 1979).
C. Methylation
Methylation reactions are primarily involved in the metabolism of
small endogenous compounds such as epinephrine, norepinephrine, dopamine, and histamine but also play a role in the metabolism of
macromolecules such as nucleic acids and in the biotransformation of
certain drugs. Unlike most other conjugative reactions, methylation leads to less polar compounds that may be less readily excreted from
the body. N-,O-, and S-methyltransferases are present in the kidney.
The cofactor, S-adenosylmethionine (SAM) is required as a methyl donor
in reactions catalyzed by these enzymes. SAM is primarily formed by the
condensation of ATP and L-methionine, and is present at
varying levels in different tissues (Eloranta, 1977). In the rat,
kidney tissue levels are approximately two-thirds that of the liver.
1. N-methylation. There are three N-methyltransferase enzymes that play a role in renal drug metabolism.
a. Histamine N-methyltransferase (HMT) (E.C. 2.1.1.8) is a cytoplasmic enzyme that requires SAM as a methyl donor and histamine as a methyl acceptor. The substrates for HMT are limited to histamine and similar amine compounds in which positions 12 and 3 are unsubstituted and there is a positive charge on the side chain. There are a large number of inhibitors of HMT including H1 and H2 receptor antagonists, diuretics, and local anesthetics (Tachibana et al., 1988).
Bowsher et al. (1983) found HMT activity in higher concentration in rat
renal tissue than in any other organ. Interestingly, the renal artery
contained a high level of this enzyme. The level of HMT in the kidney
appears to control the urinary excretion rate of histamine in the rat
(Snyder and Axelrod, 1965) and the dog (Lindell and Schayer, 1958).
Purification of rat kidney HMT revealed a protein with a molecular
weight of 33.4 to 35 kDa (Bowsher et al., 1983; Harvima et al., 1985).
The cDNA of 1.3 kb encodes a protein of 295 amino acid residues with a
calculated molecular weight of 34 kDa. After introduction of the cDNA,
Escherichia coli cells expressed HMT activity with
characteristics similar to the native enzyme (Takemura et al., 1992).
More recently, human HMT cDNA has been cloned and expressed from human
kidney (Girard et al., 1994). The amino acid sequence of this protein
was 84% identical with the HMT from rat kidney. The partially purified HMT from the cytosol of transfected COS cells had properties similar to
isolated renal cortical HMT. The structural organization and chromosomal localization of human HMT have subsequently been described (Aksoy et al., 1996).
HMT activity is higher in male rats and may be reduced by castration
(Snyder and Axelrod, 1965). Significant increases in rat renal HMT
activity have been observed after hydronephrosis (Barth et al., 1975).
Pharmacogenetic studies showed minor strain variations in levels of
renal enzyme activity among inbred mouse strains (Scott et al., 1991).
b. Phenylethanolamine N-methyl-transferase (PNMT) (E.C. 2.1.1.28) has
been demonstrated in human kidney by histochemical staining and found
to be located primarily in glomeruli, endothelial cells, and distal
tubule cells (Kennedy et al., 1995). Unlike amine-N-methyltransferase, this enzyme is specific for its methyl acceptor substrates, requiring the presence of a phenylethanolamine compound. Its endogenous substrates include norepinephrine and epinephrine. PNMT cDNA was originally cloned from bovine adrenal medulla (Baetge et al., 1986).
The cDNA was expressed in hamster kidney cells producing PNMT with a
molecular mass of 21 kDa, which was enzymatically active. The amino
acid sequence of human PNMT has been determined (Kaneda et al., 1988).
The human enzyme consists of 282 amino acids and has a Mr of 30.9 kDa.
c. Amine-N-methyltransferase (E.C. 2.1.1.49), also termed
indolethylamine N-methyltransferase, an enzyme that catalyzes the transfer of a methyl group from SAM to the amino group of indoleamines has been found in both human and rabbit kidney (Axelrod, 1962; Bhikharidis et al., 1975; Kennedy et al., 1995).
2. O-methylation.
O-methylation of phenolic groups is
important in the metabolism of neurotransmitters such as the
catecholamines and structurally related drugs. Isoproterenol is
metabolized to 3-O-methyl isoproterenol in the isolated perfused rat
kidney (Szefler and Acara, 1979). Catecholamine-O-methyltransferase
(COMT) (E.C. 2.7.1.6) is present in cytosolic (S-COMT) and membrane
bound (MB-COMT) forms that appear to have similar properties such as
using SAM as the methyl donor and requiring the presence of
Mg++ for activity. S-COMT is the predominant form, although
MB-COMT has a higher affinity for catechol substrates. These forms have now been characterized and found to have differing structures at the
N-terminus. COMT cDNAs have been isolated from several tissues and
there appears to be only one gene for COMT in rat and human. This gene
is regulated by two promoters, P1 and P2, with
P1 expressing S-COMT RNA and P2 expressing
MB-COMT mRNA (Tenhunen and Ulmanen, 1993).
detected S-COMT
mRNA in the S3 segment of the proximal tubule and the thick ascending
limb of Henle in adult rat and human kidney. The S-COMT mRNA was
detected in prenatal rat kidney as early as 18 days. Another study
using antiserum to recombinant rat COMT showed staining of proximal,
distal, and collecting duct cells of rat kidney but no staining in
glomeruli (Karkunen et al., 1994). MB-COMT was also found in kidney
tissue (Nissinsen, 1984).
COMT catalyzes the transfer of a methyl group from SAM to a phenolic
group of a catechol. Substrates include catecholamines, amino acids
such as L-dopa, and certain alkaloids and steroids. S-adenosylhomocysteine and isosteres of catechol substrates inhibit COMT in vitro (Thakker and Creveling, 1990).
The enzyme has been isolated and partially purified from rat kidney
(Darmenton et al., 1976). Rat kidney COMT activity was found to be
present at one-fourth the level found in liver (Weinshilboum et al.,
1979) and at comparable levels in human kidney (Weinshilboum, 1978).
Pharmacogenetic studies from inbred rat strains have revealed differences in inherited phenotype activity between strains
(Weinshilboum et al., 1979). COMT activity is particularly high in
newborn rat kidney as compared with other organs (Goldstein et al.,
1980) and aging is associated with a decrease in COMT affinity for
substrate (Vieira-Coelhl and Soares-da-Silva, 1996).
3. S-methylation.
Thiol methylation is important in the
metabolism of many sulfhydryl drugs such as captopril,
D-penicillamine, azathioprine, and 6-mercaptopurine (6MP).
Thiol methyltransferases are important in the detoxification of toxic
thiols and are generally excreted as sulfoxides or sulfones. In
addition, another important pathway for xenobiotic metabolism is termed
the thiomethyl shunt, acting on compounds in which sulfur has been
added from glutathione. It starts with the addition of glutathione
followed by conversion to the cysteine conjugate. This cysteine
conjugate is cleaved by cysteine conjugate -lyase to pyruvate,
ammonia, and thiol. The thiol is then methylated. Thus intermediates
formed during mercapturic acid synthesis (described below in Section
F.) may be diverted to undergo methylation and excretion rather than
N-acetylation (Stevens and Bakke, 1990).
. The cDNA sequence of cytosolic
thioether-S-methyltransferase has been determined and the enzyme
purified (Warner et al., 1995). It has a molecular mass of 29.46 kDa.
Both the nucleotide and amino sequences have significant homology with
PNMT.
The role of thioether methyltransferase to methylate seleno, telluro,
and thioethers to more water soluble onium ions suitable for urinary
excretion was proposed by Mozier and Hoffman (1990). They also
demonstrated that the renal activity of this enzyme was approximately
one-third that of the liver for substrates tetrahydrothiophene and
2-hydroxyethyl ethyl sulfide and 1/100th for 2-chloroethyl ethyl
sulfide. A similar relative value of one-third that of liver was found
for human kidney methyltransferase activity for captopril (Pacifici et
al., 1991b).
Thiopurine methyltransferase (TPMT) is a cytoplasmic enzyme that
catalyzes the S-methylation of aromatic and heterocyclic sulfhydryl
compounds such as 6MP and azathioprine preferentially. Soluble TPMT
activity was described in the kidney by Remy (1963), who found the
concentration to be much higher than that of the liver. Woodson and
Weinshilboum (1983) purified TPMT from human kidney and found it to
differ from TMT on the basis of subcellular distribution, substrate
specificity, kinetic characteristics, and sensitivity to inhibition.
Two TPMT isozymes have been purified from human renal tissue, both with
molecular weights of approximately 35 kDa (Van Loon and Weinshilboum,
1990; Van Loon et al., 1992). Human TPMT cDNA has been cloned from one
isoform using a T84 human colon carcinoma cell cDNA library. When
expressed in COS-1 cells, this cDNA encoded a protein that expressed
TPMT activity (Honchel et al., 1993). Kinetic analysis of the various
substrates for human kidney TPMT have been reported (Deininger et al.,
1994). Levels in human tissue including kidney are controlled by a
common genetic polymorphism. Eighty-nine percent of people have high activity, 11% intermediate activity, and less than 1% low activity. The isozymes of TPMT isolated were not the basis for the genetic polymorphism (Van Loon and Weinshilboum, 1990).
D. Acetylation
Drugs and other foreign compounds that are acetylated in intact
animals are either arylamines or hydrazines. Acetylation is the major
metabolic route of arylamines such as isoniazid, sulfamethazine, p-aminobenzoic acid, hydralazine, procainamide,
aminofluorene, and benzidine (Weber and Glowinski, 1980). N-acetylation
of cysteine-S-conjugates is the final step in mercapturic acid
synthesis and is discussed under that heading. The transfer of acetyl
to the hydroxyl group of choline and the sulfhydryl group of coenzyme A
are examples of endogenous acetylation but acetylation of these groups
in xenobiotics is uncommon. N-acetyltransferases (NAT) catalyze
acetylation by a double displacement (ping-pong) mechanism that is
summarized below:
|
(9) |
The human arylamine acetyltransferase genes that have been isolated
from leukocyte DNA are termed NAT1 and NAT2 (Blum et al., 1990). Both
encode proteins with an estimated Mr of 33.5 kDa. The coding regions of
NAT1 and NAT2 have 87% nucleotide identity. Expression of NAT1 and
NAT2 in monkey kidney COS-1 cells gave rise to functional proteins.
Western blots detected proteins with an apparent Mr of 33 kDa for NAT1
and 31 kDa for NAT2 (Grant et al., 1991). The NAT2 product had
identical molecular weight as NAT of human liver cytosol. NAT1 and NAT2
appear to be independently expressed.
Variability in human drug acetylation was noted 40 years ago with
people being defined as rapid or slow acetylators based on their blood
levels after administration of isoniazid. It has been more recently
shown that this was caused by genetic variability, and that NAT2 is the
locus for the polymorphism typified by the isoniazid-sulfamethazine-N-acetylation. NAT1 appears to have a discrete
polymorphism associated with the acetylation of
p-aminobenzoate and p-aminosalycilate (Vatsis and
Weber, 1994).
NAT activity has been identified in many tissues of various species.
Booth (1966) found acetyltransferase activity in the soluble fraction
of rat kidney homogenates to be less than that of liver and adrenal but
higher than in other organs studied. Pacifici et al. (1986) used the
cytosolic fraction from fetal or adult human kidneys and the arylamine,
para-aminobenzoic acid (PABA), as substrate and found NAT activity to
be 1.17 and 1.32 nmol/min/mg tissue respectively. This was one-third to
one-half the activity found in the liver. No difference was detectable between the cortex and the medulla of the kidney. NAT activity was
studied in tissues of inbred hamsters with a genetically defined Ac-CoA-dependent NAT polymorphism (homozygous rapid acetylators, homozygous slow acetylators, and heterozygous acetylators). PABA acetyl
transferase activity was comparable in kidney and liver cytosols, with
activity toward p-aminosalicylic acid, 2-aminofluorene, p-napthylamine, and isoniazid significantly less in the
kidney. In addition, there was a difference in kidney enzyme activity between the rapid acetylators and the slow acetylators for the compounds studied except for isoniazid (Hein et al., 1987a,b). An
enzyme of polyamine degradation, spermine/spermidine
N-acetyltransferase, was shown to be present predominantly in the
distal tubules of rat kidney by in situ hybridization histochemistry
(Bettuzi et al., 1995).
Kidneys from male C57BL/6 and A/J acetylated PABA at twice the rate of
kidneys from female mice. In addition, an increase in activity of NAT
during development was found in male but not female mouse kidney.
Testosterone increased NAT activity in females and estradiol decreased
activity in males (Smolen et al., 1993).
E. Glutathione Conjugation
Glutathione (GSH) is synthesized from the amino acids glycine,
L-cysteine, and glutamic acid. It is present at highest
concentration in the liver, but kidney cells also have a level of 1 to
2 µmol/g tissue. The concentration is higher in the cortex than in
the medulla (Mohandas et al., 1984), and is present in cytosol,
mitochondria, and nucleus. A sufficient supply of
L-cysteine is essential for GSH synthesis.
GSH is present in the blood at a concentration of approximately 20 µM (Anderson and Meister, 1980), and correlates with the liver concentration. GSH is degraded by the proximal tubule of the
kidney at both the luminal (Hahn et al., 1978) and basolateral membrane
(Abbott, 1984). Nearly all GSH filtered is reabsorbed from the lumen of
the proximal tubule.
GSH conjugation involves the formation of a thioether link between GSH and electrophilic compounds. This process usually facilitates detoxification and excretion but may be involved in the biosynthesis of certain compounds such as leukotriene C4.
The glutathione S-transferase (GST) family of enzymes are the proteins involved in GSH conjugation in the following reaction where RX is an electrophilic compound.
|
(10) |
), although not all have been demonstrated in kidney
tissue. There may be nucleophilic displacement from a saturated carbon,
as is seen in the conjugation of the chemotherapeutic agent melphalan.
There may be nucleophilic displacement from an aromatic carbon as seen
with the substrate 1-chloro-24-dinitrobenzene (CDNB). This has been
shown to occur in rat kidney (Temellini et al., 1995). Reactions may
occur with GSH by Michael addition, as seen with ethacrynic acid. A
metabolite of the analgesic paracetamol has been shown to undergo
glutathione conjugation in the isolated perfused kidney (Emslie et al.,
1981). The leukotriene antagonist, Verkulast, has been shown to undergo
GSH conjugation by Michael addition in rat kidney cytosol
(Nicoll-Griffith et al., 1995). GSH may also react with xenobiotics
containing strained oxirane rings, such as the BP metabolite
BP-45-oxide.
Bond-forming reactions occur at the free cysteinyl thiol group of GSH.
The GSH conjugates may then undergo further metabolism by any of a
large number of pathways to various highly polar and water soluble
metabolites that generally do not possess the biological activity of
their precursors (Shaw and Blagbrough, 1989). In mammals, the most
important of these are the mercapturic acids (S-substituted N-acetylcysteines) that are then excreted into urine or bile (Williams, 1967). Conjugation of potentially toxic electrophilic compounds with
glutathione is an important detoxification pathway.
Several systems of nomenclature have been used by workers classifying
human GST isoenzymes, and different systems are used for different
species. Mannervik et al. (1992) proposed a classifying scheme in which
each genetically distinct subunit has its own designation. There are
five classes of soluble enzymes: , µ, 
, 
, and 
; and two
classes of microsomal enzyme: microsomal GST and leukotriene
C4 synthase. These classes have significant overlap in substrate specificities and are expressed in tissue specific
patterns. Each class contains two or three subfamilies representing
different subunit types. The separate families of GST have distinct
gene structures. Class genes isolated from humans are 11 to 12 kb,
comprise seven exons, and are located on chromosome 6. Human µ genes
are 5 kb in length, contain eight exons and are on chromosome 1. Class
genes are 3 kb and contain seven exons on chromosome 11. Human ,
µ, and families contain multiple genes but only one functional
class genes exists. The number of genes is unclear. The two
membrane bound GSTs, microsomal GST and leukotriene
C4 synthase do not share sequence identity with
the cytosolic enzymes or each other. Isozymes of classes , µ, and
have been identified in kidney tissue.
These cytosolic GST isoenzymes have been purified, and all are homodimers or heterodimers containing two subunits, which function independently. Each subunit contains a GSH binding site (G-site) and a second substrate binding site (H-site). The substrate specificity can generally be determined by a small number of residues in the H-site.
There are at least 20 isoenzymes of GST in human tissue, but few of
these have been specifically identified in kidney. In human kidney
tissue, , µ, and class enzymes are present in significant
amounts (Singh et al., 1987; Tateoka et al., 1987; Beckett et al.,
1990). -class GST represents 55 to 75% of total GST protein (Singh
et al., 1987). Developmentally, the expression of -class enzymes was
up-regulated at 40 weeks of gestation, and localized primarily to the
proximal tubules (Beckett et al., 1990). The levels of µ and isozymes remained constant during development.
In the rat, genes encode the Ya,
Yc, and Yk subunits; µ genes encode Yb and Yb2,
and the gene encodes Yf. Immunoblotting has
shown that all these enzymes are expressed in cortical homogenates, with a predominance of expression of GST (Ya).
The medullary homogenates showed weaker staining. All enzymes studied
showed most intense expression in the distal tubules (Davies et al., 1993).
In the rat, immunofluorescent analysis showed that the -class enzyme
was located primarily in the proximal tubule, whereas the enzyme
was in the distal convoluted tubule. Lesser amounts of µ were
localized to the distal convoluted tubule (Di Ilio, 1991). Differential
expression of isoenzymes from these three classes has been found in
studies of rat (Guthenberg et al., 1985; Waxman et al., 1992; Johnson
et al., 1992; Rozelle et al., 1993), hamster (Bogaards et al., 1992;
Muse et al., 1994), and mouse kidney (Gupta et al., 1990). The specific
activity toward individual substrates is also quite variable (Gupta et
al., 1990; Bogaards et al., 1992). Methylation of rat kidney GST has
been shown to inhibit GST activity toward CDNB. When isolated from
human renal cortex, the GST activity toward CDNB was greater in women
than men, consistent with previous findings in rats (Butera et al., 1990). This is thought to be caused by differences in subunit composition of the enzymes.
There are clear and significant differences between the renal and
hepatic enzymes in their substrate specificities. Liver GST gene
expression has been shown to be regulated by xenobiotics, and
overexpression of GST has been demonstrated in cells resistant to
anticancer drugs (Pickett and Lu, 1989). Regulation of gene expression
in the kidney by drugs has not been reported as yet.
Induction of GST in kidney tissues has been studied. Total GST activity
against CDNB, trans-4-phenyl-3-buten-2-one (+PBO) and ethacrynic acid
in kidney cytosol have been found to be inducible by ethoxyquin. The
-class subunit Yp was increased four-fold and
the µ-class Yb2 doubled after induction with
ethoxyquin. PB and 3-MC had significant effects on liver but not kidney
tissue (Derbel et al., 1993). Activity against CDNB was also increased in rat renal tissue after administration of the hydroxyl radical scavenger, dimethylthiourea.
Reduction of rat kidney GST activity has been seen after cisplatinum
therapy (Bompart et al., 1990). Conjugation with GSH is facilitated by
the nucleophilic thiol of the L-cysteine residue. Studies
have elucidated a pathway for the GSH-dependent bioactivation of
nephrotoxic haloalkenes (Cummings and Prough, 1983; Anders et al.,
1988) as a result of either their activation, leading to higher
molecular reactivity, or to binding of the conjugate to a
macromolecular receptor where the toxicity is mediated.
The enzyme believed to be responsible for the generation of reactive
thiols from GSH conjugates of certain halogenated hydrocarbons, in the
kidney, is the rat renal cysteine conjugate -lyase (Blagbrough et
al., 1986) or C-S lyase, which has been purified by Green and Odum
(1985) (see Section II. H.) Disruption of the normal processing of
GSH conjugates, either before the formation of the mercapturic acids or
after their deacetylation, may result in the generation of reactive
products from the cysteine conjugates which produce cytotoxicity,
mutagenicity, and carcinogenicity. Some glutathione precursors of the
cysteine conjugates have been associated with kidney cytotoxicity;
2-bromohydroquinone is nephrotoxic (Elfarra and Anders, 1984) and the
GSH conjugate of hexachloro-13-butadiene is mutagenic (Green and Odum,
1985). Pickett and Lu (1989) also showed that GSH conjugates of certain
xenobiotics have been found to be toxic.
F. Mercapturic Acid Synthesis
Many GSH conjugates undergo further enzymatic modification by
hydrolysis of the glutathione-S-conjugate at the 
-glutamyl bond.
This reaction is catalyzed by the enzyme -glutamyl transferase (GT), (E.C.2.3.2.2). In addition to hydrolysis, GT can catalyze transpeptidation or autotranspeptidation. GT is an enzyme localized in the cell membrane of many cell types including kidney tubules. The
kidney, in fact, has the highest activity in several mammals studied,
including humans (Goldbarg et al., 1960; Hinchman and Ballatori, 1990).
Initially, the biosynthesis of mercapturic acids (see fig.
1 below) involves conjugation of
electrophilic xenobiotics with GSH. The next metabolic step is the
hydrolysis of the glutathione conjugate (GSR) at the -glutamyl bond
by GT. To reach the active site of GT, the GSR must be excreted
from hepatic or renal cells. It is assumed that a carrier secreting GSH
also accepts the GSH conjugate. GSH-S conjugates are hydrolyzed in the
tubular lumen (Silbernagl et al., 1982). The -glutamyl peptides are
not reabsorbed when the GT is blocked by acivicin. Mercapturic acid
is then formed by the release of glycine by hydrolysis and acetate
addition. The mercapturates may then be excreted in the urine by
filtration and secretion.
|
Using the isolated perfused rat kidney, Davison et al. (1990)
demonstrated that all the enzymes necessary for the catabolism of GSH
conjugates to mercapturates were present within the kidney. Mercapturic
acid synthesis is shown in fig. 1.
The renal GT enzyme consists of two nonidentical subunits
encoded by a common mRNA. The precursor 61.8 kDa polypeptide is glycosylated in the Golgi and processed in two subunits: a light subunit with Mr 21 kDa and a heavy fragment of 41.8 kDa (Tate and
Khadse, 1986). The catalytic site is on the light subunit. Variants in
GT have been shown to have marked electrophoretic differences caused
by their glycosylation. The structures of the human kidney GT have
been determined (Yamashita et al., 1986). In comparing rat, cow, dog,
and human kidney, Tate et al. (1988) found that renal transpeptidases
shared many antigenic determinants, but differences were noted in their
relative acceptor specificity attributable to subtle structural
differences.
The activity of GT in mammalian tissues is at its highest in the
kidney. This membrane bound glycoprotein is heavily concentrated on the
brush border of the human proximal tubular cells, particularly in the
pars recta (Endou et al., 1981). It is also found at a lower
concentration in the antiluminal border of these tubules (Glenner et
al., 1962; Curthoys and Lowry, 1973; Kugler et al., 1985; Shiozawa et
al., 1989). At these sites the enzyme is oriented in the membranes so
as to react with substrates present in the extracellular milieu (Li-Kam
Wa et al., 1996). Histochemical analysis has revealed that GT is
present in glomeruli (Sochor et al., 1980) and isolated microvessels
(Dass et al., 1981). The active site of the enzyme appears to be
located on the external surface of the brush-border membrane as
demonstrated in vesicle studies (Horiuchi et al., 1978; Tsao and
Curthoys, 1980).
The relative activity toward different substrates was determined by
Tate and Meister (1974). Kinetic studies have shown that the rates of
utilization of a -glutamyl substrate via hydrolysis or
transpeptidation depends on the pH (Cook and Peters, 1985) and on the
presence of an acceptor substrate (McIntyre and Curthoys, 1980; Tate et
al., 1988). Several classes of compounds have been shown to inhibit or
stimulate the activity of GT (Meister and Tate, 1976).
The second reaction (fig. 1) in mercapturic acid formation after
removal of the -glutamyl moiety of GSH is the hydrolysis of
cysteinylglycine or its S-derivative. This is accomplished by
peptidases that may be located intracellularly or bound to the plasma
membrane. In the rat, a peptidase that was capable of hydrolyzing
S-derivated cysteinylglycine was found localized along with GT in
the brush border membrane of the proximal tubule (Hughey et al., 1978).
This peptidase, when partially purified, was found to have broad
substrate specificities.
The final step (fig. 1) involves the acetylation of the S-substituted
cysteines. The enzyme N-acetyltransferase is discussed in detail in
Section III.D. This microsomal enzyme has been found to have its active
site on the outer surface of the endoplasmic reticulum in rat kidney
(Okajima et al., 1984). Cysteine conjugate N-acetyltransferases have
been isolated and purified from rat (Duffel and Jakoby, 1982) and pig
(Aigner et al., 1996) kidney.
The mercapturic acids are formed in both the liver and kidney (Inoue et
al., 1982). In one study of rat kidney, clearance and microperfusion
experiments with the precursor, S-benzyl-L-cysteine, demonstrated that 38% of the excreted mercapturic acid was acetylated in the kidney, primarily in the proximal tubule (Heuner et al., 1991).
Studies of the disposition of bromosulfothalein-GSH conjugate in the
isolated perfused rat kidney showed that the conjugate is metabolized
by the kidney into two major metabolites: cysteinylglycine conjugate
and diglutathione conjugate. The diglutathione conjugate is further
metabolized to the dicysteinylglycine conjugate, one of the major
urinary metabolites. The inhibition of GT with acivicin blocked the
metabolism to cysteinylglycine and dicysteinylglycine conjugates (Snel
et al., 1995). The metabolism of acetaminophen has also been studied in
the isolated perfused kidney. The acetaminophen GSH conjugate was
rapidly metabolized to 3-cysteinylacetaminophen and then more slowly to
acetaminophen-3-mercapturate (Newton et al., 1986). It is interesting
to note that the highest NAT activity is found in the proximal tubules
in a distribution similar to that of GT and the peptidase for
cysteinyl peptides (Hughey et al., 1978).
G. Amino Acid Conjugation
Amino acid conjugation reactions generally involve one of two
amino acids, either glycine or glutamate with glycine being the more
common (Smith and Williams, 1974). These reactions can occur with
substrates containing a carboxyl or an alcohol moiety, especially
substrates with aromatic groups. The acid or alcohol combines with an
amino acid to form an amide bond. The general reaction is shown below:
|
(11) |
|
).
|
|
(12) |
|
|
(13) |
). For benzoic acid conjugation,
the benzoyl CoA synthetase has been shown to have a lower specific
activity than the enzyme for reaction (13). This step may be inhibited
by substances capable of forming CoA esters, such as valproic acid. The
creation of the valproate CoA ester competes with benzoic acid
conjugation for the available ATP, CoA, and enzyme (Gregus, 1993a). The
second reaction is catalyzed by a series of enzymes known as glycine
N-acyltransferases, which are known to act on several endogenous and
exogenous substances. There are two distinct types of this enzyme
corresponding to two distinct classes of substrate. The first of these
is the arylacyl transferase (E.C.2.3.1.14), acting on arylacetic acids
such as phenylacetylCoA, and the second is arylalkyl transferase
(E.C.2.3.2.13), which acts on benzoic acid and its derivatives (Kelley
and Vessey, 1993). There is evidence from studies in animals that these
enzymes are more fully developed in neonates in the liver than in the kidney; whether this is true for humans is unknown (Ali and Qureshi, 1992).
Conjugation reactions can be limited by the amount of glycine available
in the body or by the amount of enzyme available to catalyze the
reaction. Whereas levels of glutamate do not seem to affect glutamate
conjugations in that all reactions show saturation above a
concentration of available substrate. Small organic acids such as
benzoic and salicylic will be glycinated by the kidneys into hippuric
and salicyluric acids respectively and then excreted. When this pathway
works at maximal capacity, the remainder of these drugs are
glucuronidated (Vree et al., 1992).
1. Glycine conjugation.
Glycine conjugation is the main
metabolic pathway for salicylic acid. A small increase in the carbon
side chain resulting in phenylacetic acid makes conjugation with
glycine impossible and, in humans, conjugation is carried out with
glutamine (Wan and Riegleman, 1972). Wan et al. (1972) demonstrated
that the kidney contributed more to glycination than did the liver.
Poon and Pang (1995) compared enzymatic constants for benzoic acid glycination in perfused rat kidney and liver and found the
Vmax to be 195 versus 101 nmol/min/g and the
Km to be 5.3 and 12.0 µM
respectively.
). Gregus et al.
(1993b) established that increases in the elimination of benzoic acid
after coadministration of sodium benzoate and glycine depended upon the
dose of sodium benzoate. The supply of glycine sets a maximal
conjugation rate that can be reached with an optimal concentration of
benzoate.
This is not the whole story. There are actually two factors that limit
the rates of hippuric acid synthesis, namely depletion of Coenzyme A
and the availability of glycine for conjugation. In the second reaction
(13), glycine is consumed by conjugation, whereas CoA is regenerated
each time a molecule of hippuric acid is synthesized. Once glycine
levels fall low enough to limit the rate of reaction (13), CoA is
trapped in the form of benzoyl CoA. This pool of activated
intermediates effectively denies CoA to other metabolic processes; it
also halts the production of more benzoyl CoA. In effect, this limits
the supply of benzoyl CoA for reaction (13), placing a limit on the
reaction rate (Gregus et al., 1992).
It was formerly believed that beyond the maximal rate of hippurate
synthesis benzoic acid was shunted to another conjugation pathway with
glucuronic acid (covered in III. A. Glucuronidation). More
accurate techniques for the measurement of levels of excreted glucuronic acid conjugates have revealed that glucuronidation occurs at
even very low levels of benzoic acid. Glucuronic acid conjugation with
benzoic acid increases proportionally with benzoic acid concentration,
showing no relationship with glycine availability or the resulting
maximal rate of hippuric acid formation. Glucuronidation of benzoic
acid to form hippuric acid is not a reserve pathway for benzoic acid
elimination, but rather a second pathway operating completely
independently of glycine conjugation (Schachter and Mauro, 1958).
Glycine plays the same role in the metabolism of salicylic acid via
conjugation to salicyluric acid. The rate of salicylic acid elimination
is roughly 20 times slower than the rate for benzoic acid glycine
conjugation. Liver metabolism is low, and practically all of the
salicyluric acid is formed by conjugation in the kidney. Saturation of
salicylic acid conjugation does not occur caused by a shortage of
glycine, as occurs in benzoic acid formation, but rather caused by the
saturation of the enzymes involved (Wan and Riegleman, 1972).
Metabolism of PABA follows two pathways, either by acetylation to
p-acetamidobenzoic acid (Section III. D.) and by
glycine conjugation to p-aminohippuric acid. These
reactions are localized to the kidney and liver. The quantitatively
more important reaction is the acetylation (Wan et al., 1972).
2. Glutamine conjugation.
Glutamine conjugation reactions are
limited in the body to specific arylacetic acids. One such substance is
phenylacetic acid, which can be converted in the kidney to
indolacetylglutamine in various species of Old and New World monkeys
and in humans (Smith and Williams, 1974).
H. Cysteine Conjugate -Lyase
Cysteine conjugates of aromatic drugs are metabolized principally
to the corresponding mercapturic acid. However, cysteine conjugates may
also undergo a -elimination (equation 14 below) or a transamination
reaction catalyzed by the enzyme cysteine conjugate -lyase (CCL)
(E.C. 4.4.1.13).
|
|
(14) |
). This enzyme also has been the focus of much study because
of the fact that rather than resulting in detoxification, it may be
responsible for the bioactivation of nephrotoxic cysteine and
homocysteine conjugates (Elfarra and Anders, 1984; Monks et al., 1990).
Liver and kidney are the principal sites of activity. CCL activity was localized to the cystolic and mitochondrial fraction of rat kidney
cortex (Stevens, 1985) and subsequently purified from both cystolic and
mitochondrial sources (Stevens et al., 1988).
The cDNA for rat kidney CCL has been sequenced and found to code for
a protein of 48 kDa. The cDNA was transfected into COS-1 tissue culture
cells with a resultant increase of 7- to 10-fold in cystolic -lyase
and glutaminase K activity (Perry et al., 1993).
In human kidney, -lyase activity was found in cytosolic,
mitochondrial, and microsomal fraction using
S-(2-benzothiazolyl)-L-cysteine as the substrate, with the
highest concentration found in the cytosolic fraction (Lash et al.,
1990). The -lyase activity copurified with cytosolic glutamine
transaminase K, with total Mr of 85 kDa and with a 45 kDa
subunit. The activity was inhibited by aminooxyacetic acid, indicating
that the enzyme contains pyridoxal phosphate. Human kidney CCL was
recently cloned and sequenced and found to have an overall 82%
similarity in amino acid sequence with that of rat, with 90%
similarity around the pyridoxal phosphate binding site. Expression of
the cDNA in COS-1 cells produced a cystolic enzyme with CCL and
glutamine transaminase K activity (Perry et al., 1995).
Immunohistochemical studies showed that rat kidney CCL was mainly
localized to the proximal tubule (Jones et al., 1988) with one study
demonstrating an increased concentration of enzyme in the pars recta
(S3 segment), which displays a greater sensitivity to damage from
nephrotoxic cysteine conjugates (MacFarlane et al., 1989).
The substrates studied using renal CCL have principally been certain
L-cysteine conjugates of aromatic compounds, such as S-(2-benzothiazolyl)L-cysteine, and S-(1, 2,dichlorovinyl)
L-cysteine. N-acetyl-S-(12,3,44-pentachloro-13-butadienyl)-L-cysteine
induced CCL activity in female rat kidney at low dosages, whereas at high dosages it suppressed activity (McFarlane et al., 1993). Alpha-ketoacids stimulated rat renal CCL activity (Elfarra et al.,
1987).
| |
IV. Localization of Drug Metabolizing Enzymes in the Kidney |
|---|
|
TopPreviousNextReferences
|
|---|
Those enzymes that have been localized by various studies using immunocytochemistry and enzyme activity measurements reported in this review are summarized here and appear in table 5 and fig. 2. Table 5 shows the distribution of enzymes in the kidney corresponding to fig. 2A. It appears that the cortical region is rich in metabolizing enzymes. Only in a few instances were the medullary zones studied. As seen in B of fig. 2, the proximal tubule is active in metabolizing drugs, although enzymes were found in all segments of the nephron. Many of these enzymes were localized to either the cytoplasmic or the microsomal fraction (C of fig. 2), whereas some appeared in both. These studies show the predominant distribution of drug metabolizing enzymes by regional, tubular, and cellular sites but may not be exclusive because all regions were not systematically studied.
|
|
| |
V. Effects of Renal Metabolism |
|---|
|
TopPreviousNextReferences
|
|---|
Although the kidney will generally metabolize endogenous or
exogenous chemicals to compounds with reduced biological activity, there are several instances in which metabolism will produce a toxic
intermediate that may result in mutagenesis or cell necrosis. This
topic has recently been reviewed (Anders and Dekant, 1994; Dekant et
al., 1994; Spahn-Langguth and Benet, 1992).
Instances of metabolism to active metabolites have been demonstrated
and can lead to beneficial effects. For example, the angiotensin-converting enzyme inhibitor, enalapril, is metabolized to
enalaprilat, an active and polar dicarboxylic acid metabolite. The
intrarenally formed metabolite either re-enters the circulation or
undergoes excretion into the lumen (deLannoy et al., 1990).
Investigations of renal metabolism of drugs have led to the development
of target organ-directed drug delivery systems in which systemic side
effects of drugs are avoided. For example, Elfarra and Hwang (1993)
demonstrated that the high concentration of renal -lyase facilitated
the conversion of S-(6-purinyl)-L-cysteine to the antitumor
and immunosuppressant drug 6MP by the kidney. This permits the
accumulation of much higher concentrations at its target site in the
kidney and avoids systemic toxic effects. Another example is the use of
the high concentration of -glutamyl transpeptidase in the proximal
tubule brush border to produce kidney specific production of dopamine
after the administration of the precursor -glutamyl dopa. The
concentration of dopamine in mouse kidney after injection of
-glutamyl dopa was five times higher than that seen after an
equivalent dosage of dopamine was given (Wilk et al., 1978).
Metabolism of drugs and endogenous compounds can lead to alterations in
either excretion or reabsorption depending on the pathway followed and
the activity of the enzyme. The metabolite will determine the direction
of movement. Amino acid conjugation results in loss of pharmacological
activity and a compound more readily excreted into urine via tubular
secretion mechanisms (Gregus, 1993a). Similarly, the formation of
meperidine N-oxide contributed to a more rapid excretion of that drug
by the isolated perfused kidney (Acara et al., 1981). If this route
were not functioning as in renal failure, then other metabolites, such
as normeperidine, might accumulate with attending effects. With the
exception of methylation, most conjugative metabolisms lead to more
polar compounds that may be excreted from the body rapidly. The
activity of the metabolizing enzymes also plays a role. Choline for
example will be metabolized to betaine, which is reabsorbed. However,
when the choline oxidase enzyme is saturated, choline itself moves in
the direction of excretion (Acara et al., 1979).
The most common ways in which the excretion of a substance is increased
are for the drugs to become able to bind to the carriers for excretory
transport and/or to become water soluble and filtered. Certain
biotransformations contribute to these changes (Ullrich et al., 1990).
An OH group inserted into a benzene ring renders the molecule
acceptable to the 
-aminohippuric acid (PAH) transporter, if an
electron-attracting group
(NO2
,
Cl, Br,
HCO3) is already present in the molecule.
Esterification of carboxylates decreases their affinity to the PAH
transporter. On the other hand, amino acids and oligopeptides such as
glutathione become substrates of the organic cation transport system
when they are esterified. Zwitterionic amino acids (except those that
are too hydrophyllic) become pure cations by esterification and pure
anions by N-acetylation. However, N-acetylation of uncharged amino
groups has little effect on affinity for the PAH transporter. Glycine conjugation increases the affinity of salicylate for the PAH
transporter (Ullrich et al., 1987). The metabolism of an amine to its
N-oxide leads to an increase in polarity and a drop in pKa. The
semipolar N
O linkage imparts to N-oxides a salt-like character that
makes them readily soluble in water and only slightly soluble in
organic solvents. The excretion of trimethyl amines by the renal tubule occurs predominantly as a result of the formation of an N-oxide by the
renal tubular epithelial cells followed by movement into the tubule
lumen.
Fig. 3 shows the possible pathways that
may result during renal metabolism of a drug. Entry across either the
brush border (BBM) or the basolateral membrane (BLM) is accompanied by
biotransformation of the drug (A = organic anion; C = organic
cation) to a metabolite (B or D, respectively). The metabolite may then
move in the direction of reabsorption or secretion/excretion. In the
upper section of the left panel, an organic anion such as salicylic
acid can exchange with -ketoglutarate across the BLM in a tertiary
active transport step dependent on sodium -ketoglutarate
cotransport. Glycination of salicylic acid to e.g., salicyluric acid
(indicated as B) provides a compound that more readily enters the
urine. Other possibilities are that A remains unmetabolized and is
simply excreted as the administered drug; or B could be a different
metabolite that is more likely to be reabsorbed. The lower left hand
panel depicts reabsorption of an organic anion that may occur by anion
exchange across the BBM as well as through cotransport with sodium. For example, pyrazinoate is cotransported into the tubule cell with sodium
and is returned to the blood as pyrazinoate. Biotransformation of A to
B could lead to a metabolite with a predominant pathway of either
reabsorption or secretion. The right hand panel depicts possible
pathways for disposition of organic cations. In the upper right of the
panel an organic cation such as meperidine enters the renal tubule cell
along its electrochemical gradient. It may be biotransformed to
meperidine N-oxide (D), a more polar compound that enters the tubule
fluid. Unmetabolized meperidine may exchange for a proton across the
BBM or the metabolite may follow a reabsorptive route such as would be
the case for the demethylated normeperidine. The lower half of the
right hand panel depicts an organic cation (C), such as isoproterenol
that can be reabsorbed across the BBM in exchange for a proton. Upon
entry into the cell catechol-O-methyl transferase activity produces
methylated isoproterenol that moves back into the blood. Some of the
isoproterenol may itself cross the BLM and/or a more polar metabolite
could enter the tubule fluid. In the isolated perfused rat kidney the
fractional excretion of isoproterenol decreased as the amount of the
3-O-methyl metabolite increased (Szefler and Acara, 1979).
|
In summary, although the liver plays a dominant role in drug metabolism, this review demonstrates that the kidney is metabolically active in the biotransformation of drugs. In some instances this role may, in fact, exceed that of the liver. The metabolic pathways of the kidney generally lead to a product that is more readily excreted in the urine, but in certain instances the metabolite may be reabsorbed and more active or toxic than the parent compound.
The metabolic pathways of the kidney should be considered in the administration of drugs, particularly to patients with renal impairment. Renal failure may affect the handling of drugs in several ways including drug distribution, bioavailability, and excretion. From this review, it is clear that the effects of alterations in kidney function on renal drug metabolism should also be taken into account in the determination of optimum drug therapy. Additional studies of renal drug metabolism of specific agents are needed to provide a better understanding of the role of the kidney in the disposition of drugs.
| |
Acknowledgments |
|---|
|
TopPreviousNextReferences
|
|---|
The authors wish to thank James Reuther and Teresa Schuster for assistance in the preparation of this manuscript.
| |
Footnotes |
|---|
a Address correspondence to: Margaret Acara, Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14214.
| |
Abbreviations |
|---|
ADH, alcohol dehydrogenase;
ALDH, aldehyde dehydrogenase;
AP, aminopyrine;
BBM, brush
border membrane;
-NF, -napthoflavone;
BP, benzpyrene;
CCL, cysteine conjugate -lyase;
cDNA, complementary
deoxyribonucleic acid;
COMT, catecholamine-O-methyltransferase;
CYP, cytochrome P450;
DNA, deoxyribonucleic acid;
mEH,
microsomal epoxide hydroxylase;
FAD, flavin adenine dinucleotide;
FMO, flavin-containing monoxygenase;
GFR, glomerular filtration
rate;
GSH, glutathione;
GST, glutathione S-transferase;
HMT,
histamine N-methyltransferase;
5-HT, 5-hydroxytryptamine;
LPS, lipopolysaccharide;
MAO, monoamineoxidase;
MB-COMT, membrane bound
COMT;
3-MC, 3-methylcholanthrene;
mEH, microsomal epoxide
hydrolase;
MFO, mixed function oxidase;
mRNA, messenger
ribonucleic acid;
NAD, nicotinamide adenine dinucleotide;
NADH, nicotinamide adenine dinucleotide, reduced;
NADPH,
nicotinamide adenine dinucleotide phosphate;
NAT,
N-acetyltransferases;
PABA, para-aminobenzoic acid;
PAH, -aminohippuric acid;
PAPS, 3'-phosphoadenosine 5'
phosphosulfate;
PB, phenobarbital;
PCB, polychlorinated
biphenyl;
PEA, phenylethylamine;
PNMT, phenylethanolamine
N-methyl-transferase;
SADR, specific activity difference ratio;
SAM, S-adenosylmethionine;
SAR, specific activity ratio;
sEH, cystolic (soluble) epoxide hydrolase;
ST, sulfotransferase;
STZ, streptozotocin;
TEMT, cytosolic
thioether-S-methyltransferase;
TMT, thiol-methyltransferase;
TPMT, soluble thiopurine-methyltransferase;
TTCD,
tetrachlorodibenzo-p-dioxin;
UDP, uridine diphosphate;
UDPGA,
UDP-glucuronic acid;
UDPGT, uridinediphosphoglucuronyl transferase;
UGT, UDP-glucuronyltransferase.
| |
References |
|---|
|
TopPrevious |
|---|
-lyase: An examination of the structure-activity relationships.
J Pharm Pharmacol
38:
107P.-glutamyltransferase.
Biochim Biophys Acta
832:
142-147[Medline].-glutamyltranspeptidase in the renal microvascular compartment.
Can J Biochem
59:
383-386[Medline].- and (-1)-hydroxylation.
Arch Biochem Biophys
150:
64-71[Medline].-glutamyl transpeptidase-like activity.
J Cytochem
19:
481-489.-hydroxylase (Cytochrome P-450 LA omega): Identification of a new cytochrome P450 gene family.
J Biol Chem
262:
801-810-hyroxylation of rat kidney and liver.
Jpn J Pharmacol
33:
999-1006[Medline].-hydroxylase expressed in human kidney.
DNA and Cell Biol
12:
893-899[Medline].-hydroxylases.
Biochemistry
29:
873-879[Medline].-lyase and the relationship to segment specificity of cysteine conjugate nephrotoxicity.
Mol Pharmacol
34:
621-627[Abstract].-hydroxylase activities from rabbit kidney cortex microsomes.
J Biochem
106:
194-196-lyase activity.
Drug Metab Dispos
18:
50-54[Abstract].-lyase of rat kidney cytosol: Characterization, immunocytochemical localization and correlation with hexachlorobutadiene nephrotoxicity.
Toxicol Appl Pharmacol
98:
185-197[Medline].-lyase in rat kidney by N-acetyl-S-(1,2,3,4,-pentachloro-1,3,butadienyl)-L-cysteine.
Toxicology
77:
133-144[Medline].-hydroxysteroid dehydrogenase in mouse liver and kidney.
Xenobiotica
24:
109-117[Medline].-glutamyl compounds: Biosynthesis and utilization.
Annu Rev Biochem
45:
559-604[Medline].-glucuronide: A very potent morphine metabolite.
J Pharmacol Exp Ther
251:
477-483-lyase.
FEBS Lett
360:
277-280[Medline].-lyase.
Mol Pharmacol
43:
660-665[Abstract]., µ and show selective expression in different regions of the kidney.
Xenobiotica
23:
835-849[Medline].-lyase, II: Isolation, properties and structure-activity relationships, in
Sulphur-Containing Drugs and Related Organic Compounds 2: Analytical, Biochemical and Toxicological Aspects of Sulphur Xenobiochemistry (Damani LA ed) pp 135-155,
Ellis Horwood Limited, Chichester, UK.-glutamyltranspeptidase in glomeruli and tubules of rat kidney: Effect of experimental diabetes.
Enzyme
25:
205-208[Medline].-lyase activities in rat kidney cortex: Subcellular localization and relationship to the hepatic enzyme.
Biochem Biophys Res Commun
129:
499-504[Medline].-lyase.
Drug Metab Dispos
17:
297-309[Abstract].-hydroxylases.
J Biol Chem
267:
3915-3921-glutamyl transpeptidases influence of glycosylation on the electrophoretic behavior and molecular weights of their subunits.
Biochem Biophys Res Commun
141:
1189-1194[Medline].-glutamyltranspeptidase and aminopeptidase on the external surface of the rat renal brush border membrane.
Biol Chem
255:
7708-7711.-glutamyl dopa: A kidney specific dopamine precursor.
J Pharmacol Exp Ther
206:
227-232-glutamyltranspeptidase.
J Biochem
99:
162-168.-napthoflavone-treated rats.
J Biochem
106:
248-252
0031-6997/98/501-0107$03.00/0 PHARMACOLOGICAL REVIEWS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
|
|
 |
|
  H. Quan, H. Liu, C. Li, and L. Lou 1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) Enhances the Cytotoxicity of Combretastatin A4 Independently of Mitogen-Activated Protein Kinase Kinase J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 326 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gaganis, J. O. Miners, J. S. Brennan, A. Thomas, and K. M. Knights Human Renal Cortical and Medullary UDP-Glucuronosyltransferases (UGTs): Immunohistochemical Localization of UGT2B7 and UGT1A Enzymes and Kinetic Characterization of S-Naproxen Glucuronidation J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Lickteig, C. D. Fisher, L. M. Augustine, L. M. Aleksunes, D. G. Besselsen, A. L. Slitt, J. E. Manautou, and N. J. Cherrington Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease Drug Metab. Dispos., October 1, 2007; 35(10): 1970 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ljubojevic, D. Balen, D. Breljak, M. Kusan, N. Anzai, A. Bahn, G. Burckhardt, and I. Sabolic Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones Am J Physiol Renal Physiol, January 1, 2007; 292(1): F361 - F372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Miksys, C. Cheung, F. J. Gonzalez, and R. F. Tyndale HUMAN CYP2D6 AND MOUSE CYP2DS: ORGAN DISTRIBUTION IN A HUMANIZED MOUSE MODEL Drug Metab. Dispos., October 1, 2005; 33(10): 1495 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zhang, X. Wang, K. Sagawa, and M. E. Morris FLAVONOIDS CHRYSIN AND BENZOFLAVONE, POTENT BREAST CANCER RESISTANCE PROTEIN INHIBITORS, HAVE NO SIGNIFICANT EFFECT ON TOPOTECAN PHARMACOKINETICS IN RATS OR MDR1A/1B (-/-) MICE Drug Metab. Dispos., March 1, 2005; 33(3): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Narukawa, H. Inoue, S. Kato, and H. Yokota GLUCURONIDATION OF 1-NAPHTHOL AND EXCRETION INTO THE VEIN IN PERFUSED RAT KIDNEY Drug Metab. Dispos., July 1, 2004; 32(7): 758 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Derlacz, A. K. Jagielski, A. Kiersztan, K. Winiarska, J. Drozak, P. Poplawski, M. Wegrzynowicz, K. Chodnicka, and J. Bryla AMINO-ACID-DEPENDENT, DIFFERENTIAL EFFECTS OF ETHANOL ON GLUCOSE PRODUCTION IN RABBIT KIDNEY-CORTEX TUBULES Alcohol Alcohol., March 1, 2004; 39(2): 93 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Girard, O. Barbier, G. Veilleux, M. El-Alfy, and A. Belanger Human Uridine Diphosphate-Glucuronosyltransferase UGT2B7 Conjugates Mineralocorticoid and Glucocorticoid Metabolites Endocrinology, June 1, 2003; 144(6): 2659 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Meyer, M. Podvinec, and U. A. Meyer Cytochrome P450 CYP1A1 Accumulates in the Cytosol of Kidney and Brain and Is Activated by Heme Mol. Pharmacol., November 1, 2002; 62(5): 1061 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Brueggemann and J. M. Sullivan HEK293S Cells Have Functional Retinoid Processing Machinery J. Gen. Physiol., May 28, 2002; 119(6): 593 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Pike, D. C. Mays, D. W. Macomber, and J. J. Lipsky Metabolism of a Disulfiram Metabolite, S-Methyl N,N-Diethyldithiocarbamate, by Flavin Monooxygenase in Human Renal Microsomes Drug Metab. Dispos., February 1, 2001; 29(2): 127 - 132. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. M. H. Van Aubel, R. Masereeuw, and F. G. M. Russel Molecular pharmacology of renal organic anion transporters Am J Physiol Renal Physiol, August 1, 2000; 279(2): F216 - F232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Cummings, J. M. Lasker, and L. H. Lash Expression of Glutathione-Dependent Enzymes and Cytochrome P450s in Freshly Isolated and Primary Cultures of Proximal Tubular Cells from Human Kidney J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 677 - 685. [Abstract] [Full Text]
|
|
|
|
|
|
W. Geng and K. S. Pang Differences in Excretion of Hippurate, as a Metabolite of Benzoate and as an Administered Species, in the Single-Pass Isolated Perfused Rat Kidney Explained J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 597 - 606. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
